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Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common mental disorder
characterized by inattention, hyperactivity and impulsivity. Since ADHD was formally
recognized by psychiatrists in the US in 1968, knowledge about this condition has spread to
many countries, including Vietnam. The US and Vietnam differ significantly in their perception
and management of this disorder. ADHD is an “academic disorder” in the US because the
intensifying pressure on children to succeed academically is a key factor in the emergence of
ADHD, as well as its high diagnosis rates in some states. In contrast, Vietnamese people
consider ADHD a developmental disorder of early childhood, apparently because health
professionals and laypeople alike often confuse ADHD with autism and speech disorder. Each
country also faces distinct problems with ADHD diagnosis and treatment. In the US, ADHD
prevalence differs widely between states and demographic groups. In addition, the increasing
availability of stimulant medications for ADHD and lack of awareness about their risk of abuse
have led to widespread stimulant misuse. In Vietnam, on the contrary, ADHD is a very new
condition, so it is likely underdiagnosed due to a shortage of experienced physicians and
facilities for diagnosis and treatment. Stimulant supply is severely restricted, and the Vietnamese
are much more averse to treating ADHD with medications than Americans, so the main
treatments are behavioral therapy and acupuncture. Despite the differences, responses to ADHD
have been influenced by the pharmaceutical industry, the history of medicine, and academic
pressure in both countries, though with dramatically different results.
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1. Introduction
Two countries, one name, not the same disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurological and mental disorder
that manifests itself through symptoms like “excessive motor activity, inattention, and
impulsiveness” (Lange et al., 2010). The condition is currently classified into three subtypes:
predominantly inattentive, predominantly hyperactive/impulsive, and combined (American
Psychiatric Association, 2013). ADHD is the most common childhood mental disorder in the US,
costing Americans $42.5 billion annually (Pelham, Foster, & Robb, 2007). Even before the term
ADHD was coined in 1987, this condition had been a source of controversies for American
psychiatrists, governmental agencies, teachers, and parents alike. First, many argue that
inconsistent application of diagnostic criteria have led to severe overdiagnosis of ADHD in the
US, as its prevalence reached 9.4% in 2016 (Danielson et al., 2018). Even Keith Conners,
prominent psychiatrist and the “Father of ADHD”, warned that his lifework had turned into a
“national disaster of dangerous proportion” due to overdiagnosis (Schwarz, 2013). However, the
problem with ADHD diagnosis in the US is more much complex and subtle. Some states have an
ADHD prevalence of nearly 15%, while the prevalence in some other states only reaches 5%,
indicating a need to find out the reason behind this wide discrepancy and remedy it, if necessary.
Furthermore, ADHD diagnostic criteria has become more and more lenient over time. If the
criteria are eventually loosened to the point that, for example, 15% of American children will
meet those criteria, would that be an overdiagnosis? Technically not, since the portion of people
meeting the diagnostic criteria represents the “true prevalence”, but we should question if it is a
meaningful prevalence. Therefore, aside from making sure physicians adhere to ADHD
6

diagnostic procedure, health professionals and the public must also carefully examine the
diagnostic criteria to make sure they are effectively identifying the people that need clinical help
with ADHD.
Another debate centers on the criticism that ADHD medications are given to many
children who do not need them, thus increasing the risk of unknown disturbances to the
development of their brains and performance drug abuse (Bjorn & Weyandt, 2018). The
controversy started in 1970, when the Washington Post reported on a “behavior modification
program” in Nebraska that involved giving stimulant medications to thousands of disruptive
elementary students (Schwarz, 2016). While such an outrageous situation is unlikely to occur
nowadays, there is evidence that the soaring number of prescriptions for stimulants due to rising
ADHD diagnosis rate has led to increases in stimulant diversion and abuse. The US also
consumes much more ADHD medication than European countries with a similar income level
(Scheffler et al., 2007). The question is, what are the costs and benefits of reducing stimulant
use, and how to implement it?
The problems of rapidly increasing ADHD diagnosis and stimulant use are not only
issues of science and medicine. Instead, they are strongly influenced by economic and social
factors. The marketing campaigns of pharmaceutical companies, the dominance of
psychopharmacology in American psychiatry, and rising pressure to succeed academically in the
US all play a role in inflating ADHD diagnosis and stimulant use in the US. Academic pressure,
in particular, is crucial in the establishment of ADHD as a clinical disorder. This is evidenced by
the facts that academic struggle is a major motivation for referring children to ADHD specialists,
and that changes in educational policies strongly impact ADHD diagnosis. Therefore, ADHD
7

can be considered an “academic disorder” in the US. This is not to say that ADHD is a social
construct without scientific basis, however. On the contrary, many studies have demonstrated the
biological differences between people with and without ADHD. It is precisely because many
people are suffering impairments due to ADHD that we must minimize the influence of such
social factors on ADHD diagnosis and treatment, so that people with ADHD receive the
recognition they deserve and people without ADHD do not have to bear the brunt of that label.
While ADHD originated in the US, it is no longer an exclusively American disorder. By
2003, 55 countries were using stimulants to manage ADHD (Hinshaw & Scheffler, 2014).
However, ADHD is generally considered a problem of industrial, economically developed
countries but not developing countries, as the latter have many higher priorities such as
infectious diseases and more severe mental illnesses (Hinshaw & Scheffler, 2014). This is only a
partial truth. In a developing country like Vietnam, where 64.3% of the population live in rural
area, ADHD is still a largely unheard-of condition and getting evaluated for this disorder is
remarkably difficult (Vietnam Bureau of Statistics, 2018). However, due to globalization, this
disorder was imported into Vietnam and currently receives considerable coverage in online
newspaper and websites targeting educated city-dwellers. There are also special schools for
children with a range of developmental and behavioral disorders including ADHD. However,
ADHD diagnosis in Vietnam can be highly unreliable as health professionals have limited
experience in differentiating ADHD with other childhood disorders like autism and speech
disorder. This confusion may account for the fact that the Vietnamese view ADHD more as a
developmental disorder of early childhood (before 4 years of age) than an “academic disorder”
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(usually 6 years and above) as in the US. Therefore, although the name is unchanged, ADHD has
taken on a dramatically different form in Vietnam compared to its home country, the US.
In addition, Vietnam is much more averse to ADHD medications than the US and
prefers non-drug interventions such as behavioral therapy. This divergence largely resulted from
the two countries’ differences in philosophy of medicine, pharmaceutical industry, and
educational policies. First, Western medicine was established in Vietnam less than 70 years ago,
and the country has a robust and modern system of traditional medicine. The coexistence of two
medical systems causes Vietnamese people to view Western medications as powerful but
aggressive and have harmful side effects, leading to a reluctance to give Western medications to
children for ADHD, stimulant or otherwise. Second, pharmaceutical companies in Vietnam
pursue profit just like those in the US, but since these Vietnamese companies produce herbal
supplements rather than synthetic medications, they promote traditional medicine while
emphasizing the negative side effects of Western medications for ADHD. Finally, the pressure
on Vietnamese students to do well at school is about as intense as in the US. However, this is
unlikely to lead to an increase in ADHD diagnosis and medication in the near future, since
Vietnam has almost no form of educational accommodation and limited treatment options for
students with ADHD. By examining the similarities and differences between the responses of
Vietnam and the US to ADHD, this study contributes to characterizing global variation in
attitude toward ADHD and its treatments, which can inform better policies regarding ADHD
management.
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Defining ADHD: biological and sociopsychological manifestations
The first major debate about ADHD in the West is whether it is a real disorder. To some
people, ADHD symptoms like running around, fidgeting, and making careless mistakes in
schoolwork are just normal children’s behaviors. The problem called ADHD only emerged
because many children cannot meet parents’ and teachers’ expectations that they sit still and
study for hours every day. In other words, ADHD is simply the inability of some children to
cope with the current educational system. To other people, ADHD is a concrete mental disorder
with clear biological evidence, and saying otherwise is a form of science denial. The truth is,
neither of these opposing views are entirely correct. While many studies have shown that people
with and without ADHD differ in terms of genetics, neurodevelopmental trajectory, and brain
chemistry, ADHD diagnosis and assessment of treatments must still depend on behavioral rather
than biological tests.
The first piece of evidence to support the validity of ADHD is its heritability. Research
on twins, siblings and families with adopted children has found the heritability of ADHD to be
76%, which surpasses other highly heritable mental disorders like schizophrenia (Faraone et al.,
2005; Hinshaw & Scheffler, 2014). No single gene has been found responsible for ADHD,
however. Instead, researchers have found seven genes that show “statistically significant
evidence of association with ADHD” (Faraone et al., 2005; Hinshaw & Scheffler, 2014). This is
an unsurprising result, as researchers have recognized ADHD to be a multifactorial disorder
(Nigg, 2006). However, the fact that ADHD depends on many genes poses an obstacle to
elucidating its etiology. Another problem is that the inattentive subtype and hyperactive/
impulsive subtype of ADHD are not always inherited together, suggesting that different but
10

overlapping sets of genes may be responsible for these two subtypes (Mcloughlin et al. 2007;
Nikolas & Burt, 2010). Therefore, although scientists have shown that genetic factors play a
crucial role in the etiology of ADHD, a lot more work needs to be done to connect those genetic
factors to ADHD risk assessment, diagnosis and treatment. Furthermore, aside from genes, other
factors like prenatal exposure to some substances and low birth weight also increase the risk of
developing ADHD (Nigg, 2006). Genetic studies on ADHD have thus been indispensable, but
not enough to delineate the mechanism of disease in people with ADHD.
People with ADHD also generally suffer from delays in certain aspects of neurological
development compared to those without ADHD. In 2011, Nakao et al. analyzed data from
fourteen structural neuroimaging studies on ADHD and found that people with this condition
have lower total gray matter volume compared to control. The authors also found that increasing
age and usage of stimulant medication correlated with greater total volume of gray matter,
suggesting that people will ADHD may catch up with non-ADHD people over time and with the
use of stimulants. Similarly, Shaw et al. found that children with ADHD have delayed brain
cortex development compared to control by about 3 years (2007). In sum, these studies show that
people with ADHD likely go through the same neurodevelopmental process as people without
this condition, only more slowly, which explains why ADHD symptoms sometimes abate or
disappear in adulthood. However, these neurodevelopmental traits vary widely among people
with ADHD, so they cannot serve as a basis for predicting and diagnosing ADHD. Furthermore,
traits like brain cortex development can only be measured by monitoring a child over many
years, so it is not a good diagnostic tool.
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ADHD has also been linked to reduced activity of the dopamine neural pathway, an
important signaling pathway related to reward and motivation in the brain. In 2009, Volkow et
al. found that adults with ADHD who had not taken medications had lower dopamine receptor
availability in the left hemisphere than control. Although the sample size was small (53 ADHD
patients and 44 controls), this result may explain how stimulants can alleviate ADHD symptoms,
since these substances enhance dopamine signaling in the brain. The problem is, dopamine is
linked to so many neurological functions that scientists have not been able to elucidate exactly
how defects in the dopamine pathway lead to ADHD symptoms like inattention and
hyperactivity. Furthermore, it is unknown whether the dopamine pathway and the delayed
neurodevelopment previously outlined belong to the same or separate mechanisms of ADHD
pathogenesis. Overall, genetic risk factors, delayed neurodevelopment, and reduced dopamine
signaling are important pieces of the puzzle, but they are far from enough to construct the full
picture of ADHD.
The aforementioned biological traits are only three among the many factors that scientists
have examined to find the causes of ADHD, but they are the ones that produced the most striking
results. Overall, however, the etiology of ADHD is still largely unknown, and no biological
factor has been found to correlate with ADHD consistently enough to serve as a diagnostic test
for this condition. In fact, it seems that no single biological or environmental factor can account
for all cases of ADHD (Nigg, 2006). At the moment, the only traits that are consistently
associated with ADHD and easy to measure are behavioral patterns including inattention,
hyperactivity and impulsivity. The DSM-V stipulates that for an ADHD diagnosis, the patient
must have 6 or more traits from a list of inattentive behaviors or a list of hyperactive/impulsive
12

behaviors. The inattentive behavior list includes items like “often distracted by extraneous
stimuli” and “often forgetful in daily activities”, while the hyperactive/impulsive behavior lists
includes “often runs about or climbs in situations where it is inappropriate” and “often has
difficulty awaiting turn” (Rabiner, 2013). The most obvious problem is that different observers
may disagree on how “often” a child expresses those symptoms, and thus disagree on whether
that child has ADHD. More importantly, behavioral patterns may change depending on the social
context. This means that given the current ADHD diagnostic criteria, social norms and
expectations can influence ADHD diagnosis.
One example of how social factors can affect ADHD diagnosis has to do with social
norms related to hyperactive behaviors. Hyperactivity is historically the most characteristic
symptoms of ADHD, evidenced by the fact that the prototype of ADHD was called
“hyperkinetic reaction of childhood” in the DSM-II (1968). Basing ADHD diagnosis on
hyperactivity is problematic because hyperactive behaviors are perceived as more socially
acceptable in boys than in girls, and more in children than in adults. This could explain why
ADHD diagnosis rate has always been higher in boys than in girls. Indeed, the male-to-female
ADHD ratio was 10 : 1 in 1980 and between 9 : 1 and 4 : 1 in 1994 (Bergey & Conrad, 2018). In
addition, boys are more likely to have the hyperactive subtype and aggressive behaviors as
comorbidity, while girls are more likely to have the inattentive subtype and emotional troubles as
comorbidity (Hinshaw & Scheffler, 2014). In other words, it could be that boys and girls have
the same rate of ADHD, but this condition does not manifest as hyperactivity in girls due to
social norms against hyperactive behaviors in this group, leading to a lower diagnosis rate of
ADHD in girls. Since health professionals have paid more attention to ADHD in girls recently,
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the male-to-female ADHD ratio has risen to 5 : 2 in 2016, but was still clearly unbalanced
(Danielson et al., 2018). Similarly, health professionals recognize that as children with ADHD
enter adulthood, their hyperactivity may abate while other symptoms related to inattention and
impulsivity persist (Mayo Clinic, 2017). This is because in adults with ADHD, the impulse to
fidget or run around is dampened by social norms. These examples are only a subset of the many
ways that social factors can impact ADHD manifestation, diagnosis and treatment, as we will
soon see. ADHD has a biological basis, but at the moment it cannot be reduced to biochemical
pathways in the same way as tuberculosis or diabetes. Therefore, investigating how social,
economic and cultural factors influence the ADHD epidemic, which is the purpose of this study,
will prove essential in optimizing ADHD diagnosis and treatment.

2. ADHD in the US: historical development and current situation
The ADHD controversy started in the 1970s, when this condition was still known by its
early name of “hyperkinetic reaction of childhood”. Since then, the debates have both continued
to the present and stretched into the past, as health professionals, critics and laypeople disagree
over the past, present and future of ADHD. While professional opinions hold that ADHD is a
medical condition with deep roots in history, critics point out how non-medical factors like
corporate investment and increased social benefits for people with learning difficulties played a
large role in the development of ADHD into “America’s No. 1 Psychiatric Disorder”. More
recent debates center on whether ADHD is overdiagnosed and overmedicated. The problem is,
there has yet to be an objective criterion on what qualifies as “overdiagnosis” and
“overmedication”, so what one person interprets as overdiagnosis may mean better detection of
ADHD cases for others. Furthermore, these debates detract from the most tangible issues right
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now, which are divergent ADHD diagnostic rates between different states and demographic
groups and the lack of a fixed ADHD prevalence due to changing diagnostic criteria. The US’
prodigious consumption of stimulant medications compared to the rest of the world is also a
cause of concern, as efforts to ensure proper use of these dangerous substances have not kept up
with the rates of stimulant diversion and misuse.

The birth of ADHD
Critics have often questioned whether ADHD is a real disorder or just a product of
mandatory education and other social factors, prompting many scientists to try to validate ADHD
by elucidating its biochemical mechanism. Another way is to show that ADHD has a long
history. Afterall, if ADHD is a real disorder, it must have affected people in past centuries as
well, so references to ADHD or its symptoms in historical documents can show that this
condition is not simply the product of pharmaceutical companies and a flawed educational
system. The 2010 article “The history of attention deficit hyperactivity disorder” by Lange et al.
offers a meticulous and highly cited chronology of research on ADHD and its purported
prototypes, ranging from the 18th century to the time of its publication. Through this article,
readers can see how isolated observations of ADHD-like symptoms by physicians, usually
decades apart in time, eventually converged to define one single disorder that was officially
recognized in 1980 by the APA as “attention deficit disorder” (ADD) in the DSM-III. This
article is thus a powerful piece of evidence that ADHD truly exists. However, not all events in
the history of ADHD support this conclusion. Alan Schwarz, author of the book ADHD Nation
(2016), and other critics have noted that the birth of ADHD was not simply due to an
accumulation of scientific research, but also factors such as the pharmaceutical industry and
15

policy changes. Therefore, in the US, history is also an area of contention in the ADHD debate.
It is important to examine both sides’ arguments to see whether ADHD is a product of biology or
society, or a combination of both.
The first two references to ADHD-like conditions presented by Lange et al. occurred in
Europe in the 18th and 19th centuries, long before the start of mandatory education. In 1798, the
famous Scottish physician Alexander Crichton published three books on the physiology and
pathology of various mental illnesses and dedicated one chapter to “Attention and its Diseases”.
There, he described people who are incapable of paying consistent attention to any single object,
which may be innate or due to diseases. These symptoms, termed “alterations of attention” by
Crichton, may appear at an early age and hamper the child’s education, but they often abate with
age (Crichton, 1798). Since these characteristics seem to closely align with today’s definition of
ADHD, Crichton’s books have been taken as evidence that ADHD has existed since the late 18th
century. The next reference was in an 1844 children’s book by the German physician Heinrich
Hoffmann. The book has a character called “Fidgety Philipp”, who could not sit still, disregarded
his parents’ demands, and caused a mess at the dinner table. Because Hoffmann was an
accomplished psychiatrist, many people have pointed to “Fidgety Philipp” as evidence that
ADHD is not a modern disorder restricted to the US.
The 20th century witnessed major landmarks in the circuitous history of ADHD in the
West (Lange et al., 2010). In the first few decades, several research groups described psychiatric
conditions similar to ADHD in children. Since children’s mental health was a scarcely studied
field at the time, these reports were sporadic, and each group came up with a different name for
the condition they observed. These names included “defect of moral control” (George Frederic
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Still, 1902), “hyperkinetic disease of infancy” (Franz Kramer and Hans Pollnow, 1932),
“minimal brain damage” (various researchers, 1930s to 1950s), “hyperkinetic impulses disorder”
(Laufer et al., 1957), and “minimal brain dysfunction” or MBD (Oxford International Study
Group of Child Neurology, 1963). While these terms cover a wide range of meanings, most
focus on hyperactivity and the impairment of some brain capacity. Moreover, the descriptions
from Crichton’s “alterations of attention” to “defect of moral control” to MBD have become
increasingly based on biological abnormalities (speculated, since none had been found at the
time), which reflects the increasing reliance on reductionism in Western psychiatry (Healy,
2002). In any case, this group of disorders was gaining professional interest. Too much interest
in some cases, since at one point 99 symptoms were attributed to MBD, covering nearly all
emotional and behavioral problems of childhood (Hinshaw & Scheffler, 2014). Professional
interest in this group of disorders culminated in its recognition in the second and third editions of
the DSM, the APA’s official guide for diagnosing mental disorders in the US. The DSM-II
(1968) included a new condition called “hyperkinetic reaction of childhood” with symptoms
such as “overactivity, restlessness, distractibility, and short attention span”, which is very similar
to current understanding of ADHD. The condition was then redefined as “attention deficit
disorder (with or without hyperactivity)” (ADD) in the DSM-III (1980) and finally “attention
deficit-hyperactivity disorder” (ADHD) in the 1987 revision of the DSM-III.
While psychiatrists disagreed over the terminology, two major breakthroughs occurred
regarding stimulants as a potential treatment for this condition (Lange et al., 2010). The first one
took place in 1937 at Emma Pendleton Bradley Home (Rhodes Island), the first facility in the
country built specifically to cater to “disturbed and difficult kids” (Bradley Hospital, n.d.;
17

Schwarz, 2016). The medical director, Charles Bradley, accidentally discovered that the
amphetamine-containing stimulant Benzedrine caused a marked improvement in school
performance and calmed the impulsiveness of the children. This astounding result was largely
ignored by the scientific community, however, perhaps because the treatment did not correspond
to a specific diagnosis (Bergey & Conrad, 2018). In addition, psychoanalysis was still the
preferred treatment for mental disorders in the US at the time (Lange et al., 2010; Schwarz,
2016). However, some researchers still took notice of Bradley’s discovery and continued his
work, which led to the seminal study by Leon Eisenberg and Keith Conners in 1963 showing that
the stimulant Ritalin improved attention and reduced the impulsiveness of “disturbed children”.
ADHD also became the lifework of Conners, who created the first questionnaire to diagnose this
condition and was regarded the “Father of ADHD” (Schwarz, 2016). While the inclusion of
“hyperkinetic reaction of childhood” in the DSM-II marked the formal birth of ADHD, Conners’
work on Ritalin and the diagnostic questionnaire marked its de facto emergence as it allows
physicians to handle ADHD in practice.
While Lange et al.’s account presents a natural history of ADHD, in which a previously
obscure disorder slowly gained acceptance and official recognition, other authors emphasize
different milestones in the road ADHD took to become America’s No. 1 psychiatric disorder. For
example, Allan Schwarz – a prolific critic of the overdiagnosis and overmedication of ADHD –
disagreed with Lange on two points in his 2016 book ADHD Nation. First, Schwarz questioned
the inclusion of Crichton and Hoffmann as early physicians who documented ADHD. He argued
that Crichton believed distractibility was normal in kids and only a problem in adults, and that
Hoffmann’s story of Fidgety Philipp was merely for entertainment rather than symbolizing any
18

medical condition (Schwarz, 2016). Indeed, if Hoffmann had recognized fidgeting behaviors as
pathological, being a famous psychiatrist, he would likely have done more to publicize this
condition rather than just incorporating it into a children’s book. Second, Schwarz mentioned a
significant and overlooked event. Shortly after the Eisenberg and Conners reported on the
effectiveness of Ritalin, a representative of its manufacturer – CIBA Pharmaceuticals – came to
their office with a check for $5,000 “for further studies”, which Eisenberg accepted.
To be clear, we can assume that Eisenberg and Conners are honest scientists who cared
about the children and would continue studying Ritalin for its potential clinical benefits rather
than the CIBA’s money. However, we cannot overlook the fact that $5,000 was likely a big
assistance to Eisenberg and Conners in performing further trials and spreading the good news
about Ritalin. Psychotropic drugs could not be marketed directly to the public at that time, so
physicians were the only “consumers”, as they were responsible for prescribing medications.
Therefore, investing in clinical trials was the best way to quickly promote the sale of their drugs.
This event also shows that drug companies have paid very close attention to new research results
about their products. If they could see the significance of Eisenberg and Conners’ study before
most health professionals and approach them so quickly, we can assume that CIBA and other
drug companies have approached most other experts in this field as well. And while there is no
evidence to suspect any of those experts with malpractice, many studies have shown that funding
from pharmaceutical companies strongly correlates with favorable results for those companies
(Sismondo, 2008). Therefore, since the earliest studies on the effects of stimulants on inattentive
children, pharmaceutical companies’ sponsorship has played a role in establishing stimulants as
the first-line treatment for ADHD.
19

Other important events not included by Lange et al. are the implementation of the
Individuals with Disability Education Act and the changes to Supplemental Security Income
(SSI) eligibility in 1990-1991. These policy changes guarantee educational accommodations,
services and benefits to children with ADHD and their families, so ADHD diagnosis rate rose
dramatically in the 1990s throughout the country (Bergey & Conrad, 2018; Hinshaw &
Scheffler, 2014). This indicates that aside from professional acceptance and corporations’
influences, the push for better performance in schools and universities also helped elevate
ADHD to its current prominent status in the US. The role of pharmaceutical companies and
academic pressure in ADHD diagnosis and medication will reappear in more detail in Part 3.
Through these diverging narratives on the development of ADHD, we can learn two lessons. On
one hand, although the historical dates and names remain unchanged, by shifting our perspective
a little and focusing on other events, we can arrive at a remarkably different origin story for
ADHD. On the other hand, these diverging account of the birth of ADHD represent the larger
divide in the ADHD discourse. This divide, which started in 1970 following report that many
children are being treated with Ritalin in Nebraska, is present in all discussions pertaining to
ADHD (Schwarz, 2016). Between supporters and critics of the mounting ADHD diagnosis and
medication use, everything about the condition seems open to debate, including its clinical
validity, its rate of diagnosis, the merits of stimulants, the forces behind increasing diagnosis rate
and treatment, and so on. These debates will appear in subsequent sections, starting with a
fundamental question: How many people are affected by ADHD?
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Problems with ADHD diagnosis
ADHD is one of the most frequently diagnosed childhood mental disorders in the US,
according to data from the Centers for Diseases Control and Prevention (CDC) (Akinbami et al.
2011). From 1998 to 2011, the diagnosis rate of ADHD among school-aged children (5 to 17
years old) have steadily risen from 6.9% to 11% (Akinbami et al., 2011; Schwarz, 2016). By
2016, 9.4% of children 2 to 17 years old had ever been diagnosed, corresponding to 6.1 million
children (Danielson et al., 2018). In contrast, the latest version of the DSM (DSM-V) estimates
that 5% of children have ADHD globally (APA, 2013). This discrepancy between US prevalence
and suggested global prevalence has prompted many critics like Alan Schwarz to argue that
ADHD is overdiagnosed in the US. One highly cited reason for this overdiagnosis is that
physicians do not have enough time and resources to evaluate each child’s condition (Hinshaw &
Scheffler, 2014; Schwarz, 2016). Many studies have also found that a large number of physicians
do not adhere to established protocols to diagnose ADHD, leading to a high probability of
misdiagnosis (Sciutto & Eisenberg, 2007). This inconsistent application of standard diagnostic
criteria, along with the social pressure to diagnose more cases of ADHD from the pharmaceutical
industry, schools, and even parents, has led many critics to suspect that physicians throughout
the US are diagnosing more ADHD cases than they should.
However, this argument is oversimplified and does not reflect the variety of problems
with ADHD diagnosis in the US. First, we have no means to judge whether the current diagnosis
rate of 9.4% or the APA’s 5% global estimate is more accurate due to the subjective nature of
ADHD diagnosis, possible cultural differences in assessing ADHD, and the variety of data
collection methods in existing prevalence studies. Advocates of ADHD thus often argue that the
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rising diagnosis rate of ADHD in the past 50 years is due to increased awareness about the
condition, which would be partially correct. Second, despite the recognition that ADHD is easily
misdiagnosed, some researchers assert that those misdiagnoses include both false positives and
false negatives, and there is no evidence that the rate of ADHD is inflated overall (Sciutto &
Eisenberg, 2007). Most importantly, ADHD diagnosis in the US suffers from several systematic
problems that cannot be explained by inconsistent diagnosing practice alone, such as the wide
discrepancies in ADHD prevalence between states and demographic groups. In addition to
standardizing ADHD diagnosing practice, we must also address the causes of these problems in
order to achieve a reasonable and meaningful rate of ADHD diagnosis in the US.
Compared to the popular critique that ADHD is overdiagnosed, the wide variation in
ADHD prevalence among US states receives much less media coverage and presents a much
clearer proof that ADHD diagnosis in the US needs improvement. At the low end of the
spectrum, Nevada and New Jersey only have 4.2% and 5.5% diagnosis rates of ADHD in 2011,
respectively. In contrasts, the rates for Arkansas and Kentucky are 14.6% and 14.8%, nearly
triple the rates in Nevada and New Jersey (Visser et al., 2014). There is little reason to believe
that children in Arkansas are three time as susceptible to ADHD as children in Nevada, so the
most likely explanation is that ADHD is being overdiagnosed in some states, especially in the
South and the Midwest (Fig. 1). The reason for this overdiagnosis is not certain, but we will see
in Part 3 that it most likely has to do with differences in educational policies among US states.
Since the label of ADHD exacts a large financial and emotional toll on children, families and the
states (Travell & Visser, 2006; Hinshaw & Scheffler, 2014), this issue must be resolved as soon
as possible to reduce unwarranted distress and unnecessary use of stimulant medications.
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Figure 1. Variation in ADHD diagnosis rate in children 4 to 17 years of age between US
states in 2011 (Visser et al., 2014)
Aside from geographic locations, many other demographic factors including race,
ethnicity, household characteristics, and health insurance can influence the rate of ADHD
diagnosis. For example, for children between 4 and 17 years of age, white children were most
likely to receive an ADHD diagnosis (12.2%), followed by black children (11.9%), and children
of other races (7.2%) (Visser et al., 2014). Furthermore, Hispanics were only half as likely to
receive an ADHD diagnosis than other children (Visser et al., 2014). When household
characteristics and other factors have been controlled for, Hispanic children become the group
with the second-highest chance of receiving an ADHD diagnosis, although their rates are still far
below those of white children (Fig. 2, data from 1998 to 2007) (Morgan et al., 2013). These
disparities could reflect different levels of awareness about ADHD, access to mental health
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services, psychiatrists’ bias, cultural differences, and so on. While more effort must be made to
ensure equal access to mental health information and services for racial and ethnic minorities, we
should also be careful about imposing out cultural beliefs about ADHD on another group. For
example, if a community is averse to the label of ADHD due to cultural and family values, in all
but the most extreme cases, the community and families within it should decide how best to raise
and educate their children.

Figure 2. Racial disparity in the chances of receiving an ADHD diagnosis at pre-school,
1st grade, 3rd grade, 5th grade and 8th grade (Morgan et al., 2013)
The question of whether ADHD is overdiagnosed is further complicated by the fact that
ADHD has no fixed “true prevalence”. Instead, the “true prevalence” of ADHD depends on its
diagnostic criteria. At the moment, the DSM-V recommends that ADHD be diagnosed by two
24

checklists, one with 9 symptoms related to inattention and another with 9 symptoms related to
hyperactivity/ impulsivity. The patients are diagnosed with either predominantly inattentive
ADHD or predominantly hyperactive/impulsive ADHD if they have at least 6 traits in either list.
If the patients have at least 6 traits in each list (which means at least 12 in total), the diagnosis is
combined ADHD. In addition, an ADHD diagnosis must satisfy several other conditions, such as
that symptoms must interfere with daily activities and appear before the age of 12 (Rabiner,
2013). These thresholds are rather arbitrary but necessary because there is no clear-cut boundary
between a child with mild ADHD and an energetic but otherwise normal child. If any of these
thresholds changes, for example if the number of symptoms required in each list increases to 7
out of 9, the “true prevalence” of ADHD will necessarily change. In fact, since the 1980,
diagnostic criteria for ADHD has been gradually loosen, which contributed to the increase in
ADHD prevalence (Hinshaw & Scheffler, 2014). For example, in 2011, the APA changed the
lower age limit for an ADHD diagnosis from 6 to 4 years old (Goodman, 2011). In addition,
while the DSM-IV stipulates that symptoms must appear before 7 years of age for an ADHD
diagnosis, the DSM-V increases this upper limit to 12 years old. The latter also states that ADHD
symptoms do not have to cause “clinically significant impairment” to warrant a diagnosis, as
long as those symptoms reduce the quality of daily functioning (Rabiner, 2013). Clearly, these
changes would lead to cases of ADHD that would not have been diagnosed under the old criteria.
Is it a wise decision to make ADHD diagnostic criteria more and more lenient? The APA
likely has a good motive, since relaxing ADHD diagnostic criteria helps more children become
eligible for federal support and educational accommodations. Some authors also interpret this as
a good, or at least harmless, change because the old criteria might have missed some valid cases
25

of ADHD (Sciutto & Eisenberg, 2007). We must be careful about how far to push this ADHD
label though, since a greater number of cases means more people are eligible for stimulant
medications and become targets of pharmaceutical companies’ marketing efforts. In addition, no
matter how much we relax the ADHD diagnostic criteria, there are always people who struggle
with school or work due to low ability to concentrate, but are not impaired enough to warrant an
ADHD diagnosis. These people will also perform better with stimulants and educational
accommodations. Then, how can we justify giving medications and accommodations to people
with ADHD symptoms that start before 12 years of age, but not if they started between 12 and 13
years of age? And since the ability to sustain attention is normally distributed, as seen in Fig. 3,
those people who narrowly miss the ADHD label are very difficult, if not impossible, to
distinguish from those with mild ADHD (Hinshaw & Scheffler, 2014). Therefore, the benefits of
relaxing ADHD diagnostic criteria and increasing the number of cases should be carefully
weighed against negative consequences like increasing availability of stimulants and federal
spending on ADHD.
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Figure 3. Ability to sustain attention and control impulses is normally distributed.
On the national level, is it hard to say whether ADHD is overdiagnosed in the US
because of insufficient data on the actual ADHD prevalence and the changing diagnostic criteria.
The current ADHD prevalence of 9.4% in children between 2 and 17 years of age is not an issue
in itself. Rather, this statistic is only problematic if it includes people not meeting current
diagnostic criteria but received the ADHD label due to substandard diagnosing practice, but there
has been little evidence of this. Another problematic case is if everyone in this 9.4% group meets
the current diagnostic criteria for ADHD, but some of them may only have mild symptoms that
would not have satisfied previous criteria. Then, the issue is technically not “overdiagnosis” of
ADHD, and people who think such cases should be excluded should advocate tightening of the
diagnostic criteria. But who should decide if those mild cases count as ADHD: psychiatrists,
parents, teachers, or the affected children and adults? Until all parties reach a consensus on what
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ADHD diagnostic criteria, a possible solution is specifying whether each case of ADHD is mild,
moderate or severe, and restrict medication use for mild cases. That way, we can reduce the risks
associated with excessive diagnosis and medication use for ADHD while giving affected people
the help they deserve. Finally, rather than repeat unsupported claims about ADHD under- or
overdiagnosis, we should first address well-documented local problems with ADHD diagnosis
like the wide discrepancy in ADHD prevalence among states and demographic groups.

Stimulant medications: use and misuse
I was diagnosed with Dyslexia when I was 6 years old but there is no medication for it. I
have never had ADHD […] However, as a kid I didn't pay attention in school because I
hated it and that in turn made me have problems with teachers. I think my dislike for
school made me want to start taking [ADHD] medication in high school because it
simply made getting work done easier. […] Adderall would give me a sort of tunnel
vision and I wouldn’t think about anything else but the homework. When I got to
college, I was struggling to get work done and the medication was helping me. I also
started to notice side effects around then. The bad ones were mostly anxiety and
paranoia after the positive effects were done. That’s when I went to the doctor and told
him I had been taking [Adderall] illegally for a few years and that I needed it and on the
first visit he immediately wrote a prescription. […] I only filled the prescription a few
times until I decided it wasn’t a good habit because you start to rely on it. I know many
people who rely on it because I think they're addicted, not because they need it. Back
then I took it 5 of 7 days for about a year, now I take it a few times a semester.
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R, a student of Colby College, Waterville, ME (personal communication, 2019)
Like the question of ADHD overdiagnosis, the increasing use of stimulants for ADHD
has sparked a long and fierce debate. Some people argue that treating ADHD with behavioral
therapy rather than medications constitutes malpractice because it was essentially withholding
the most effective treatment (Schwarz, 2016). Other points to the negative and unknown side
effects of stimulants on developing children and cases of stimulant misuse like the account above
to caution against medicating every child with ADHD. Again, just like the debate on ADHD
overdiagnosis, the debate on ADHD medication have dragged on for decades without any
satisfactory conclusion partly because the two sides cannot agree on what is an “appropriate”
level of stimulant use for ADHD. Some people think stimulants should not be prescribed at all
for ADHD, others approve medical use of stimulants in adults but not children, while the APA
states that anyone 6 years and above can take stimulants. On one hand, more research is needed
to decide what level of stimulant use offers the best compromise between the clinical benefits
and risks of these drugs. On the other hands, there is evidence that efforts to control stimulant
use have not kept up with the soaring number of prescriptions, leading to widespread misuse of
stimulants as performance-enhancing drugs and other consequences. This section thus offers an
overview of what stimulants are, how they are being used to treat ADHD in the US, and the
stakes involved in making them widely available to children and adolescents.
Stimulant refers to a class of synthetic chemicals that, as its name implies, increase the
level of focus and energy in the user. Most of the stimulant medications in the US contain either
amphetamine (Adderall, etc.) or methylphenidate (Ritalin, Concerta, etc.), which have similar
structures and activities (Fig. 4). Both types of stimulant work to increase the effect of
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catecholamines signaling in the brain, some of which are involved in maintaining alertness, focus
and motivation (Hunt, 2006; Volkow et al., 2009). That is why everyone, with or without
ADHD, experiences increased attention and focus after taking stimulants. In terms of treatment
effectiveness, the potency of amphetamine is about twice that of methylphenidate (Safer, 2016).
Even when used at their optimum dosages, amphetamine still seems to have slightly stronger
effect (the optimum dosage of amphetamine is usually half that of methylphenidate) (Hodgkins,
Shaw, Coghill, & Hechtman, 2012). However, amphetamines were widely abused in the US
from the 1940s to the 1970s, so it was not a medication of choice to treat young children
(Rasmussen, 2008). Consequently, even though amphetamine was the first kind of drug that
proved effective in alleviating ADHD symptoms, the stimulant most prescribed for children with
ADHD has always been methylphenidate (Safer, 2016).

Figure 4. Structure of amphetamine (left) and methylphenidate (right)
(Hodgkins et al., 2012)
Although amphetamine has proved to be a drug with high potential for abuse, this
compound and the related drug methylphenidate have been prescribed to millions of children and
at an increasing rate in the US. Stimulants are the first line of treatment for ADHD in adults and
children 6 years and above. In 2016, 62.0% of school-age children with ADHD were prescribed
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stimulants, while only 46.7% received behavioral therapy (CDC, 2016). Along with increase in
ADHD diagnosis rate, stimulant prescription and consumption have risen sharply in the last 30
years. Fig. 5 charts the global consumption of methylphenidate from 1990 to 2013, which shows
a roughly 24-fold increase in this period from 3 tons to 72 tons. Most of this consumption
occurred in the US (International Narcotics Control Board, 2015). Moreover, between 1996 and
2013, the US has increased its amphetamine production quota by 40 times, from 2.3 tons to 91.6
tons (Safer, 2016). This is similar to the amount produced at the peak of America’s first
amphetamine epidemic in 1969 (80-100 tons), raising concerns about a second outbreak of
amphetamine abuse (Rasmussen, 2008). In comparison, methylphenidate production only
increased by 8.2 times, from 11.8 tons to 96.8 tons (Safer, 2016). A possible reason why
amphetamine has overtaken methylphenidate is that more and more adults are taking stimulants
for ADHD, and adults may prefer the more potent amphetamine to methylphenidate.

Figure 5. Amount of methylphenidate consumed globally from 1990 to 2013. One daily dose of
methylphenidate equals 30 mg, as defined by the INCB, so the amount of methylphenidate
consumed globally in 2013 was about 72 tons (INCB, 2015).
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Compared to other countries, the US has an extraordinarily high rate of ADHD
medication use. Despite the fact that 55 countries have started using ADHD medication by 2003,
the US still accounts for over 80% of the global methylphenidate consumption in 2013 (Hinshaw
& Scheffler, 2014; International Narcotics Control Board, 2015). In addition, while research has
shown that the use of ADHD medication by a country increases with growing gross domestic
product (GDP), the US’s consumption is much higher than would be predicted by its GDP (Fig.
6) (Scheffler et al., 2007). Interestingly, many European countries like France and Germany have
higher rates of medication use among people with ADHD (82.7% and 84.1%, respectively) than
the US, but still lower ADHD medication use per child because of their lower ADHD prevalence
(Hodgkins et al., 2013; Scheffler et al., 2007). This suggests that those European countries only
recognize cases of ADHD with moderate to severe symptoms, but medicate most of those cases.
This may be a good strategy that the US can adopt to reduce the risk of stimulant misuse while
maintaining the benefits of stimulant medications for people with ADHD.

Figure 6. Correlation between ADHD medication use and per capita GDP of OECD countries in
2003 (Scheffler et al., 2007).
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Stimulants are safe when used properly. However, nonmedical use of stimulants is not
uncommon in the US, leading to addiction and adverse medical consequences. Both
methylphenidate and amphetamine are Schedule II substances, meaning they have high potential
for abuse and may lead to psychological or physical dependence. This is a major reason why the
American public is anxious about giving stimulants to children and teenagers. This anxiety is not
unfounded, as a 2015 survey shows that about 600 000 Americans consumed pharmaceutical
stimulants (except methamphetamine) nonmedically in the previous month (Rasmussen, 2008).
In particular, between 5 and 35% of college students report that they have used prescription
stimulants nonmedically (Bjorn & Weyandt, 2018). The account of R, quoted at the beginning of
this section, is particularly enlightening. Like many other college students, R got Adderall from
his roommate, highlighting the risk of diversion of prescription stimulants by students with
ADHD (R, personal communication, 2019). One reason for this diversion may be the widespread
perception that stimulants are “virtually harmless” while they are anything but, causing students
to have little qualm about sharing their prescription stimulants with a friend (Rasmussen, 2008).
The truth is, prescription stimulants have a range of unpleasant side effects including appetite
loss, weight loss, tiredness, insomnia, negative emotions, and irritability (Hodgkins et al., 2012).
In rare cases and with prolonged use of stimulants, patients may experience even psychosis and
suicidal thoughts (Schwarz, 2016). One may argue that the decision to use stimulant medications
nonmedically and in spite of negative side effects is a personal choice, just like the decision to
smoke or consume an excessive amount of alcohol. On the population level, however, the
soaring availability of stimulants in the US constitutes a public health problem because it has led
to an increasing number of adverse health events due to improper stimulant use. For example, the
number of Emergency Department visits related to ADHD stimulants has more than doubled
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from 2005 to 2010, with 39 – 50% of those visits due to nonmedical use (Fig. 7) (SAMHSA,
2013). In short, increasing prescription of stimulants and their improper use by those with and
without ADHD have led to many negative health consequences, so the government and health
professionals must exert a better control on prescription stimulants to curb their nonmedical use.

Figure 7. Emergency Department visits due to ADHD stimulant use from 2005 to 2010
(SAMHSA, 2013)
Besides the nonmedical consumption of stimulants, there are also issues with how
physicians are prescribing these drugs. For instance, R’s psychologist was willing to prescribe
him Adderall even though R had never been diagnosed with ADHD. This example illustrates the
fact that even health professionals need to be more aware of the dangers of nonmedical use of
stimulants. Another problem is the age at which children can be prescribed stimulants. Out of
concerns for the unknown effects of stimulants on the developing brain of young children, the
American Academy of Pediatrics (AAP) recommends that children 4 to 5 years of age with
ADHD should try behavioral therapy first and only use medications if moderate or severe
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symptoms persist (Brown et al., 2011). Nevertheless, in 2016, 18% of children 4 to 5 years old
with ADHD were still prescribed stimulants (CDC, 2018). While it is unclear if stimulants were
absolutely necessary for those children, use of these dangerous psychotropic drugs in such young
children should be minimized. In addition, aside from stimulants, people with ADHD are often
prescribed other psychotropic drugs to manage comorbidities like conduct problem, anxiety,
depression, autism spectrum disorder, and sometimes even to cope with the side effects of
stimulants (Schwarz, 2016). This polypharmacy not only burdens the children’s developing
bodies but also carries health risks since we do not know enough about the effects of combining
multiple psychotropic drugs (Schwarz, 2016). Therefore, aside from reducing nonmedical use of
stimulants by laypeople, health professionals must also reflect on their prescribing practice and
work to minimize ADHD medication use in very young children as well as unnecessary cases of
polypharmacy.
The future of stimulant use in the US is uncertain. On one hand, the American public has
become more cautious and knowledgeable of the risks of improper stimulant use, partly thanks to
a growing number of books and news articles on the topic. For instance, a 2012 review paper on
public attitudes toward ADHD treatments noted that parents and teachers generally preferred
behavioral interventions to medications (Bussing et al.). On the other hand, the prescription and
sale of stimulants may continue to rise due to a few factors. First, behavioral therapy is more
time-consuming than stimulant use. And while the cost to the family depends on the type of
insurance they have, behavioral therapy typically costs more than medications (Fertig &
Gutierrez, 2017). Consequently, regardless of the parents’ preference, children may still be put
on medications to manage their ADHD to reduce cost. Second, despite knowing about
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stimulants’ side effects, parents may decide that improved academic performance is a higher
priority. Finally, adult ADHD diagnosis is on the rise thanks to marketing campaigns by drug
companies (Safer, 2016; Schwarz, 2016). Since adults in the US outnumber children by many
times and use more ADHD medications over their lifetime, stimulant use in the near future is
likely to increase even though stimulant use in children is leveling off.
Overall, ADHD in the US is a moving target because we lack comprehensive data on its
prevalence and a consensus on what the “appropriate” level of medication use should be. Due to
the changing diagnostic criteria, it is hard to say whether the current ADHD prevalence of 9.4%
is too high or not. Nevertheless, a high ADHD prevalence would lead to elevated production and
consumption of stimulants, which increases the risk of adverse health effects from stimulant
misuse. To solve this problem, the US may adopt the same strategy as European countries like
France and Germany, which only diagnose and medicate people with severe ADHD symptoms.
An alternative solution is reserving medication for people with moderate and severe ADHD, so
that people with mild ADHD can still receive educational accommodations without being
subjected to the risks of unnecessary stimulant use. This is also the strategy that health
professionals advocate in Vietnam, though with mixed result, as we shall see in Part 4.

3. Social factors behind the American ADHD epidemic
Evidence-based practice is a hallmark of Western medicine and stipulates that medical
diagnosis and treatment should be objective and grounded in empirical research. However, it
would be naïve to think that medicine, which is so intertwined with culture and society, can ever
be free from the influence of historical and social factors. This is especially true for mental
36

disorders in general and ADHD in particular. Among the historical and social forces that can
inflate ADHD diagnosis and medication use are the interest of Big Pharma, the dominance of
reductionism and psychopharmacology in Western psychiatry, and increasing demand for
academic achievement in the US. The influence of these factors on ADHD does not mean
ADHD has no scientific validity. Instead, it means the US government, health professionals and
public must restrict the influence of these social factors so that ADHD diagnosis and treatment
can follow best practice in medicine.

Influence of pharmaceutical companies
The pharmaceutical industry plays a direct role in shaping the extraordinary popularity of
stimulant medications in the US despite their side effects and risk of abuse, especially through its
extensive marketing efforts. Alan Schwarz has written extensively on this topic in his 2016 book
ADHD Nation, which is the source of many of the facts cited below. Americans’ current
spending on ADHD medications is about $10 billion dollar a year, which represents a 50-fold
increase compared to the 1990s (Frances, 2017). ADHD medication is an extraordinary lucrative
business, and drug companies are doing everything in their power to maintain this revenue. A
central part of their marketing campaign is direct-to-consumer advertising (DTCA).
DTCA began in 2001 and violated the United Nations’ 1971 Convention on Psychotropic
Substances, which prohibits the direct advertisement of those substances to the general public
(United Nations, 1971). In fact, the US is one of the only two countries that allow the direct
marketing of psychotropic drugs to consumers, which could explain why the US account for over
80% of the global methylphenidate consumption (Safer, 2016). This advertising strategy must
have been highly effective in increasing drug sale, given that pharmaceutical companies
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dramatically increased their DTCA spending from $55 million to $4.2 billion dollar between
1991 and 2005 (Bergey & Conrad, 2018). In this situation, the government should have created
strict regulations and closely monitored drug advertisements to make sure pharmaceutical
companies cannot make unfounded claims about the efficacy of their products. The US Food and
Drug Administration (FDA) did the exact opposite. According to Hinshaw & Scheffler (2014), in
1997, the FDA relaxed DTCA regulations so that advertisements would not have to list all
potential side effects in detail, only major ones, which clearly benefitted pharmaceutical
companies at the expense of consumers’ health. In fact, lack of awareness about the potential
side effects of prescription drugs has fueled many public health crises in the US, including the
current opioid epidemic and amphetamine epidemic (Rasmussen, 2008). Therefore, while
pharmaceutical companies are culpable for making money at the expense of public health, the
US government is also an enabler in the marketing of ADHD medications.
Unsurprisingly, a major problem with drug advertisements is that they usually exaggerate
the benefits of the drugs, deemphasize unpleasant side effects, and manipulate the hopes and
fears of consumer to convince them to buy the product. One example is the advertisement for
Adderall XR shown in Fig. 8. The image, depicting a mother embracing her son, is brimming
with positivity and smiles. Meanwhile, the cursive exclamation “Finally!” conveys a sense of
relief and freedom from distress – some of the implied effects of Adderall. The advertisement
claims that Adderall will help the child produce “schoolwork that matches his intelligence”. This
is a rather insidious statement, since it temps parents to blame all academic failures on ADHD
rather than the kids or the family. After all, it is not a pleasant thing to admit that one’s children
deserve less than a B+ on assignments. The advertisement also implies that Adderall can
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improve family relationship and friendship. Therefore, most parents seeing this advertisement
would feel obliged to consider the possibility that their children have ADHD, just in case they
are being held back from good grades and barred from good relationships by this disorder. In
contrast to the prominent slogan, the paragraphs on safety information are written in fine print to
detract attention from possible side effects. Obscuring the safety information section is a
common strategy to many drug advertisements, as seen from the screenshot of an online
advertisement for Vyvanse (another stimulant for ADHD) in Fig. 9. The safety information on
this advertisement is legible, but it is cramped into a very small window that only displays three
lines at a time. To read the information, the viewers have to scroll down very slowly, which
requires a lot of skills and patience. In other words, this advertisement was designed to strongly
discourage viewers from reading the safety information.
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Figure 8. Adderall XR advertisement from 2005 by Shire (Schwarz, 2013)
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Figure 9. Advertisement for Vyvanse, another stimulant medication for ADHD, on the
Psychology Today website (https://www.psychologytoday.com/us)
Another, more subtle way to promote medication sale is advertising the condition. Fig. 10
shows another advertisement by the manufacturer of Adderall XR, this time about adult ADHD
and directed to health professionals. Since the audience is adults, the advertisement adopts a
much darker tone, relying on fear tactics to convince physicians and psychiatrist to check for
ADHD in depressed patients. The problem is, when physicians actively look for a condition with
subjective diagnostic criteria like ADHD, they are more likely find it due to confirmation bias.
Overall, the marketing strategies employed by pharmaceutical companies aim to convince
physicians and consumers to diagnose more ADHD cases and use more medication, regardless of
whether this increase in warranted.
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Figure 10. Flyer about adult ADHD by Shire, 2006 (Feloni, 2013)
Aside from investing in DTCA, pharmaceutical companies spend large sums of money
on people and organizations that can help them promote their products. First, manufacturers of
ADHD medications have funded many prominent researchers in the field of ADHD pathology
and treatment, including the “Father of ADHD” Keith Conners at the nascent stage of ADHD, as
noted in Part 2. Another prominent researcher with ties to pharmaceutical companies is Joseph
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Biederman, a prolific scientist who published about 300 papers from 1995 to 2005, or 2.5 papers
per month on average. In particular, 13 of his papers on ADHD have been cited over a thousand
times. Most of his work aims to demonstrate the severity of ADHD, argue that ADHD is
underdiagnosed, and affirm the effectiveness of ADHD medications. Then, in 2008, it was
revealed that Biederman and two of his associates had accepted $1.6 million from drug
companies without declaring it (Schwarz, 2016). We cannot claim that scientists who receive
funding from industry will modify their results to serve the sponsors’ interests; however,
research have shown that the results of studies and clinical trials funded by pharmaceutical
companies usually align with the sponsor’s interests, possibly due to overreporting of favorable
results or underreporting on negative results (Sismondo, 2008). Furthermore, due to the funding
from pharmaceutical companies, ADHD medications may undergo much more research than
non-drug treatments, creating the impression that ADHD medications are safer and more
effective than non-drug treatments while that may not be the case. Moreover, even an advocate
organization like Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD)
has received nearly a million dollars from the manufacturer of Ritalin (Schwarz, 2016).
Scientists should be committed to discovering truths and advocate organizations are meant to
prioritize the needs of people with ADHD, not corporate interests. Therefore, the fact that they
may be biased toward drug companies is a warning sign that mechanisms to protect the health of
people with ADHD and the general American public are being eroded by capitalist interests. It is
high time that the government stepped in to regulate the ADHD medication market.
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Reductionism and the rise of psychopharmacology
Big Pharma can exert a strong influence on doctors, patients and families, but this factor
alone is not enough to explain the commitment of the majority of scientists, health professionals
and the public to ADHD medications in the US. ADHD is not a special case in this regard.
Nowadays, most mental disorders in the US are managed by pharmaceuticals, a practice that
constitutes the field of psychopharmacology. An authority on this topic is David Healy, who
wrote a comprehensive history of how American psychiatry came to rely on pharmaceuticals in
The Creation of Psychopharmacology (2002). Here, I refer to several important events and ideas
in this book to explain why how the historical events have made medications, rather than
psychotherapy, the current first-line treatment for ADHD.
The 20th century saw a major paradigm shift in Western psychology. The primary
treatment method for mental disorders in the US in the first half of the 20th century was
psychoanalysis, but it was quickly replaced by pharmacotherapy (Healy, 2002; Schwarz, 2016).
This was not merely a change between two treatment methods, but also the transition between
two paradigms. On one hand, psychoanalysis represents the tradition of vitalism, which holds
that there must be something more than chemistry and anatomy – a vital force as it was called –
that differentiates humans from inorganic matters. Therefore, psychoanalysts rejected the notion
that mental processes like free will, responsibilities and human thoughts completely depend on
chemical reactions, and sought to heal the mind through conversations and social interactions. In
contrast, psychopharmacology holds that mental processes are based on chemical reactions, so
carefully designed drugs can produce desired effects in the brain and cure mental illnesses.
Therefore, psychopharmacology is a reductionistic branch of science, since it describes
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neurological processes in terms of nerve cells and chemicals. Before the middle of the 20th
century, psychiatrists did not believe that chemical could cure mental conditions, so vitalism
dominated over reductionism in psychology. However, three major events that occurred in the
20th century overturned this order: the rise of chlorpromazine, the antipsychiatry movement from
1965 to 1975, and the discovery of receptors involved in schizophrenia (Healy, 2002).
Chlorpromazine was the first effective antipsychotic drug discovered. Originally
developed by a French pharmaceutical company as a sedative drug, it was given to psychotic
patients in 1951 and brought about dramatic improvements. People who had been unresponsive
and delirious suddenly woke up, and remember who they were, and apparently cured of their
psychosis. This result was replicated with enthusiasm throughout France, offering young and
ambitious psychiatrists the first glimpse into a new world where previously incurable mental
illnesses could be cured by synthetic chemical compounds. Note that the effect of amphetamine
on inattention as hyperactivity was discovered before chlorpromazine, but at that time inattention
and hyperactivity were not considered a disorder. Nevertheless, psychoanalysts did not fell out of
favor immediately, since there were not many powerfully psychotropic compounds like
chlorpromazine. Indeed, most psychiatrists in the 1950s believed that both drugs and therapy
were needed to cure mental illnesses (Healy, 2002).
From 1965 to 1975, however, the value of psychotherapy came under intense scrutiny
due to a widespread anti-psychiatric sentiment. Inspired by the civil right movements, people
started to condemn psychiatry as a repressive institute that incacerated and punished people who
did not conform to social expectations. Influential essays like The Myth of Mental Illness (1961)
argued that disorders treated by psychoanalysts were not real since they did not have biological
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causes and were treated by non-physical interventions like conversation therapy. Psychoanalysis,
once the mainstay of Western psychiatry, became thus a threat to psychiatry itself. In that time of
crisis, psychiatrists needed to assert the legitimacy of their profession, and they did so by
distancing themselves from social matters and relying more and more on biochemical
explanations. Afterall, if they could demonstrate problems of the human psyche with
biochemical tests, their opponents would not be able to discredit them anymore. In that context, a
previously ignored theory gained popularity: the reductionistic idea that neurological functions
depended on the interactions between compounds called neurotransmitters with receptors in the
brain (Healy, 2002).
The theory of receptors and neurotransmitters proved to be the perfect tool for
psychiatrists to prove that mental disorders are physical entities rather than figments of their
imagination. This theory arose when scientists found that a minute amount of lysergic acid
diethylamide (LSD) caused dramatic effects in people, which implied that LSD acted as a “key”
to open some “lock” in the brain. Therefore, they called the “lock” a “receptor”, and its key a
“neurotransmitter”, implying that the binding of neurotransmitters to receptors would trigger
mental processes. This theory did not receive much support from psychiatrists initially because at
the time, technology had not developed enough to find concrete evidence about such receptors.
Moreover, this theory evokes a disturbing idea that our brains are not much different from
machines, in which the right effects can be achieved by pushing the right buttons. However, as
vitalism became the weakness of psychiatry, it was abandoned in favor of reductionistic
biochemical explanations of the brain’s functions. Opiate receptors were found in 1972,
providing a major breakthrough in this direction. Next, psychiatrists developed the dopamine
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hypothesis of schizophrenia, which signified that mental illnesses have measurable biological
causes as well, just like other diseases. This was the proof they needed that psychiatry was a
legitimate medical profession, even though the hypothesis was not complete at the time and had
been unproven until now. Pressured by the anti-psychiatric movement, psychiatrists embraced
the dopamine hypothesis of schizophrenia with enthusiasm, and have since then wielded
biochemical models as proof of the legitimacy and scientific rigor of their profession (Healy,
2002). Once psychiatrists started to reconceptualize problems with the human psyches in terms
of biochemicals, they came to rely on synthetic chemicals as treatments. That is the story of how
Western psychiatry shifted from vitalism to reductionism, leading to the present situation where
medications are the main treatment of most mental disorders. Pharmaceutical companies, as
astute as ever, quickly capitalized on this shift and started to invest billions of dollars in
developing and marketing psychotropic medications, giving rise to the present ADHD stimulant
industry.
This story seems to suggest that had reductionism not replaced vitalism in psychiatry, we
would not have to worry so much about psychotropic drugs flooding the US market, but that is
not true. The existence of neurotransmitters and receptors is a biological fact and would be
discovered sooner or later. The problem was the timing of that discovery: if it did not coincide
with the anti-psychiatric movement, psychiatrists might not have abandoned psychoanalysis and
switched to psychopharmacology so completely. Overall, the issue is not that vitalism is better
than reductionism, but that reductionism alone is not enough. Reductionism works by
simplifying the complex biochemical network in the body so that scientists can focus on a few
pathways of interest at a time. This approach has worked well for many metabolic diseases like
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diabetes since their mechanisms are relatively simple and the affected organs are well
understood. In contrast, the biochemical pathways involved in many mental disorders like
ADHD has not been elucidated, so we still do not know how to minimize the side effects of
stimulant medications and how they may impact children’ developing brain. Many researchers
on ADHD have also noted that this disorder is incredibly complicated, so it must be analyzed at
the neurobiological as well as sociocultural levels (Nigg, 2006). Therefore, one solution for the
future may involve adopting a new form of vitalism – system biology – which emphasizes the
interconnectedness and synergy between biochemical components (Fontecave, 2010). System
biology also reminds us that pharmaceuticals are not “magic bullets” that only hit the targets we
want, so a multimodal approach to complex disorders like ADHD is always better than
psychopharmacology alone.

ADHD and the increasing demand for academic achievements
While the reductionistic mindset of Western psychiatry and the marketing campaigns of
pharmaceutical companies fueled the US’ reliance on stimulants for ADHD, the third factor –
demand for academic achievements – influences ADHD by augmenting the rate of diagnosis. As
asserted by Hinshaw and Scheffler in The ADHD Explosion (2014), ADHD is essentially an
“academic disorder” in the US. In other words, the main motivation for families and individuals
to seek out a diagnosis and treatment for ADHD is to improve academic performance (or work
performance for adults). This brings back questions about to what extent ADHD is the
medicalization of aspects of normal behaviors and how the birth of ADHD depended partly on
social forces.
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People with ADHD indeed differ from people without ADHD biologically, as seen in
Part 1, but biological differences alone are not enough to define a new disorder. According to
Nigg (2006), a disease or disorder must have “clinical validity”, defined as “the extent to which a
disorder hangs together statistically (as a syndrome), is exhibited by impaired children who need
help, responds to treatment, and has other meaningful external correlates”. In other words, a true
clinical condition must be an impairment found in a number of people and associated with a set
of biological traits or other markers. Impairment is the key here, as it can help to distinguish a
pathological trait from a merely abnormal trait. For example, having gray eyes is abnormal, but
since it causes no impairment, it is not a disorder. Then, does ADHD cause enough impairment
to count as a disorder? Currently yes, but that has not always been the case.
One major reason why ADHD is causing a significant impairment to affected children is
the rising demand for uniformed performance and academic competition. As Hinshaw and
Scheffler assert, low attention span was an innocuous trait that did not significantly impact
quality of life until the start of mandatory education a few decades ago (2014). Now that children
are expected to sit still in class for hours, absorb a lot of knowledge five days a week, and do
homework outside of class, people with hyperactivity and less-than-average capability to
concentrate would have lower academic performance and struggle more to gain the same
achievement as their peers. A few decades ago, when people could make a living without a high
school or bachelor’s degree, the impairment caused by this low academic performance would
have been small. However, since the 1970s, the US job market has been increasingly polarized,
leading to the expansion of high-paying, skilled jobs as well as low-paying, unskilled jobs, while
well-paying, semiskilled jobs declined (Kalleberg, 2011). High educational attainment became a
49

prerequisite for earning a high-paying or well-paying job, making students and their families
more and more anxious about their academic performance. For the same reasons, the value of a
college education, especially at elite institutions, has increased dramatically since the 1970s,
while the enrollment at top colleges and universities remained virtually unchanged, as shown by
Bound et al. (2009). The result has been intensifying academic competitions at all educational
levels, which made the impairment caused by ADHD a lot more severe than it was a few decades
ago. In addition, students are employing a variety of strategies to enhance their competitiveness,
including obtaining special accommodations while taking the SAT. Bound et al. also found a
correlation between academic competition and special accommodation seeking behavior, as
states with higher levels of competition also have higher percentages of students taking the SAT
under nonstandard conditions. Since ADHD is one of the conditions that make students eligible
for special accommodation, the escalating academic competition in the US incentivizes the
public to recognize ADHD as a medical condition, so that affected students can receive
medications and special accommodations to boost their grades.
Schools provide another source of academic pressure and incentive for diagnosing and
medicating more cases of ADHD. As academic pressure intensified on the personal level, the US
as a whole also set higher expectation on students’ performance at schools and in standardized
tests. Hinshaw and Scheffler (2014) found that ADHD diagnosis rates significantly increased
after the implementation of the No Child Left Behind Act (NCLB) in 2002. This act made
schools’ funding dependent on the students’ academic performance, which motivated schools to
seek the ADHD label for their weaker students so that their grades can be improved through
medications and academic accommodations or excluded from the schools’ overall performance
50

(Hinshaw & Scheffler, 2014). In addition, Hinshaw and Scheffler found that states with the
highest ADHD diagnosis and medication rates, like Arkansas and North Carolina, are those that
already had educational accountability policies similar to the NCLB before 2002. Overall, the
escalating academic pressure at both personal and national levels in the US is incentivizing
teachers, parents and children to accept the ADHD label so that they can enhance their
competitiveness and improve the schools’ overall performance. If the US did not have such a
high demand for academic achievement, ADHD may still exist as a medical condition, but it
would certainly not reach the prodigious scale it has today.
Even the emotional burden and negative consequences associated with ADHD, such as
risky behaviors, substance abuse, and divorce, also depend at least partly on the social context.
Mandatory education brought along the expectation that children sit still in class and follow
instructions for hours at a time. Since children with ADHD have difficulty fulfilling those
expectations and also struggle academically, they may perceive themselves as incompetent and
undesirable. Academic failure, in this age of meritocracy, also reduces a child’s chances to make
friends and create conflicts within the family. The insecurity, frustration, stigma and conflicts
that build up within the child may account for the high rate of comorbidity seen in children with
ADHD. In addition, the risky behaviors, substance abuse, and divorces in people with ADHD are
much more likely caused by these negative emotions than by the inattentive and
hyperactive/impulsive symptoms characteristic of ADHD. Overall, most of the impairment cause
by ADHD is mediated by social forces.
Since there are social forces that exacerbate the impairment caused by ADHD, would
restraining those forces be a more sustainable strategy to manage this disorder than stimulants? A
51

social treatment for ADHD is not impossible, but will take a lot of efforts on the national level.
People are born with a range of talents and aptitudes, so not everyone will thrive in the academic
environment of high schools and colleges nowadays. If the government can create better job
opportunities for people who do not succeed academically but have other skills and talents, then
people with mild ADHD symptoms will not be pressurized into getting a diagnosis and
stimulants. Another priority is considering how to respond to further pressures on the US
population to increase their focus, academic performance and work productivity in the future. In
ADHD Explosion, Hinshaw and Scheffler (2014) argue that providing proper, evidence-based
treatment to all those diagnosed with ADHD because it will significantly reduce ADHD-related
costs to the economy. While there is no problem with using ADHD treatments to reduce workrelated injuries due to inattention and the associated public health costs, we must be cautious
about using stimulants to increase work productivity, especially in people with only mild ADHD.
Given the capitalist economic structure in the US, economic gain from increased productivity
will benefit the employers much more than the workers. Using stimulants to enhance
performance at work means the workers must bear the burden of side effects as well as the risk
of abuse while receiving only a small share of the profit. More importantly, not all of the loss
productivity caused by ADHD is actual loss. As seen in Part 2, humans’ ability to concentrate is
normally distributed, we can assume that there as many people with impaired attention as people
with enhanced attention. In other words, the “loss productivity” caused by people with ADHD,
which is the differential between their productivity and the average person’s, is already
compensated for by other people with naturally enhanced attention. Overall, the aim of ADHD
treatments should be to reduce personal impairment and distress, and behavioral therapy and life
coaching can be used to improve work productivity. However, using stimulants to increase work
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productivity, especially in people with mild ADHD, is a slippery slope that could vastly magnify
the current problems of diversion and misuse of prescription stimulants in the US.
ADHD is not a clear-cut medical condition, and treatment choice depends on many
factors besides scientific findings. The US’s decision to rely on stimulants for ADHD
management has been a result of the rise of psychopharmacology in Western psychiatry and
fueled by the marketing efforts of pharmaceutical companies. In addition, the impairment
associated with ADHD, which is critical in establishing ADHD as a medical condition,
originates from biological factors as well as the increasing demand for academic achievement in
the US. ADHD in the US is thus an “academic disorder” because its emergence and treatment
are inextricably linked to the desire to improve academic performance, both at individual and
national levels. While this means ADHD is partly a social construct, it does not negate the
validity of ADHD or the values of ADHD diagnosis and treatments. Whether we call ADHD a
disorder or not, people with high level of inattention and hyperactivity/impulsivity still suffer a
disadvantage and need help to succeed in the present American society. The job of psychiatrists
is accurately identifying (diagnosing) those people and deciding what extent of help they need
(special accommodation, behavioral therapy, medication, etc.). Furthermore, since social forces
account for much of the emotional burden associated with ADHD, behavioral therapy and life
skills development will be indispensable in maximizing treatment effectiveness and reducing
ADHD-related adverse health outcomes.
While I have focused on stimulant medications so far, there are many other treatments for
ADHD. They include behavioral therapy, non-stimulant medications, neurofeedback, and so on.
In particular, the use of complementary and alternative medicine (CAM) to treat ADHD has been
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growing in popularity recently (Hinshaw & Scheffler, 2014). Among these non-stimulant
treatments, only behavioral therapy has significant clinical evidence of effectiveness, while
neurofeedback is promising but not yet an established treatment for ADHD (Hinshaw &
Scheffler, 2014). In Vietnam, however, non-stimulant treatments including behavioral therapy
and traditional medicine are used in the majority of ADHD cases. Due to lack of research and
clinical experience with ADHD, the management of this condition in Vietnam is much less
standardized and evidence-based than in the US, leaving a lot of room for social and cultural
factors to shape the Vietnamese’s response to ADHD.

4. Vietnamese perspective on ADHD
In the past two decades, an enormous amount of information about ADHD has entered
Vietnam from outside sources, successfully capturing the public’s attention. However, neither
Vietnamese health professionals nor laypeople had prior experience in dealing with this
condition, leading to inconsistent responses. On one hand, some professional sources in Vietnam
tend to regurgitate information about ADHD based on Western publications, even when some of
the information is not relevant to the Vietnamese context. On the other hand, the Vietnamese
public has disregarded a part of that “official information” and reinterpreted ADHD based on
their social reality. A middle ground exists between these approaches as well, as some authors
and physicians agree with Western sources on most details about ADHD, but also modify some
part to appeal to a Vietnamese audience, especially to reduce the important of medications
compared to psychotherapy in ADHD treatment. Overall, professional and lay sources of
information on ADHD in Vietnam vary widely in how much they adopt from Western sources.
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ADHD is a very new concept in Vietnam, so the current prevalent is low and finding
experienced physicians to diagnose this condition is difficult. The Vietnamese conceptualization
of this condition also differs from the Americans’ in several ways. While ADHD is an “academic
disorder” in the US, Vietnamese parents often think of it as a developmental disorder of early
childhood because of its similarity to autism and speech disorder. Regarding ADHD treatments,
Vietnamese parents are much more wary about the serious side effects of ADHD medications
than Americans, so they may choose not to use medications even when prescribed. Behavioral
therapy seems to be the primary treatment for ADHD in Vietnam, followed by life skill
coaching, play therapy, group therapy, counseling, and so on. Alternative treatments include
acupuncture and herbal supplement, but their effectiveness is still open to question. Overall,
although ADHD was imported into Vietnam from the Western world, this disorder has been
reshaped by the local social context and lost many characteristic features of ADHD in the US.

Historical and current states of ADHD in Vietnam
Research into ADHD in Vietnam has a much shorter history than in the US. The first
reference to ADHD that I found was in a Vietnamese translation of the Mental Health Guideline
of the International Statistical Classification of Diseases and Related Health Problems (ICD-10).
The ICD-10 was published by the World Health Organization (WHO) in 1992, while the
Vietnamese translation was from 1999 (Nguyễn et al., 1999). Aside from the DSM-V published
by the APA, the ICD-10 is the most commonly used guideline to diagnosed ADHD over the
world. This Vietnamese translation was most likely created to help with systematic diagnosis of
mental illnesses in Vietnam, but it cannot prove whether ADHD was studied and diagnosed in
Vietnam at that time. In fact, among the few Vietnamese journal articles and graduate theses that
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I have found on ADHD, the earliest Vietnamese study referenced dates to 2001 (Đặng & Hoàng,
2001). A brief Google Scholar search further reveals how little academic attention ADHD has
received in Vietnam compared to the West. While the keyword "attention deficit hyperactivity
disorder" yields about 559,000 results in English, its Vietnamese translation “tăng động giảm chú
ý” only yields 48 results. To be sure, a large number of Vietnamese research papers and theses
may not be accessible through Google Scholar. However, given the large stigma against mental
disorders in Vietnam and the absence of references to Vietnamese studies on ADHD before
2001, ADHD research seems to be in its nascent stage in Vietnam. However, a graduate thesis
form 2006 asserts that ADHD was mentioned in many news articles, so this condition has been
known among the Vietnamese, or at least the urban educated population, for more than 10 years
(V. C. Trần, 2006). This was further supported by my observation that many popular online
newspapers in Vietnam have published several articles on ADHD in the past three years.
Therefore, while the public seems highly interested in this condition, scholarly research has not
been able to keep up. One possible reason is the large volume of research done on ADHD in
other countries, which might make Vietnamese academics think there is not much left to research
on this condition. The lack of Vietnamese studies on ADHD is a disadvantage because evidencebased treatment for ADHD in Vietnam will have to be adapted from foreign studies, which may
not suit the local cultural and social climate.
Available data, though far from comprehensive, indicate that ADHD is diagnosed less
often in Vietnam than in the US. There is no comprehensive data set in Vietnam with national
ADHD prevalence, but a study on 821 students aged 8 to 11 in Ho Chi Minh City found that
2.3% of those children had significant ADHD symptoms and another 2.7% had slight ADHD
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symptoms (Lê, 2013). Another study on 400 elementary school students in Ha Noi found a
higher ADHD prevalence of 6.3% (Nguyễn, 2012), which would be higher than combined
prevalence for children and youths since elementary students tend to have higher ADHD
prevalence than older youths. Overall, the national prevalence of ADHD is likely much lower
than the above estimates, since densely populated urban areas like Ho Chi Minh City and Ha Noi
have higher awareness about ADHD than rural areas. In fact, 2017 data from the Institute for
Health Metrics and Evaluation (Washington, US) showed that the prevalence rate of ADHD in
the 5 to 14 age group in Vietnam is 1.2%. Although ADHD prevalence may vary with
geographical and cultural contexts, it is likely that this low diagnosis rate is due to lack of
awareness about this condition, since it has not been receiving professional attention for a long
time in this country. Moreover, there are only three cities in Vietnam where one can get
evaluated for ADHD from reliable professionals, which are Ha Noi, Da Nang, and Ho Chi Minh
City (Fig. 11) (Lương, n.d.). Big hospitals in other provinces may offer this service as well, but
people generally prefer going to Ha Noi or Ho Chi Minh City to get higher quality of care.
Therefore, people who live far away from these cities will face some difficulty in getting
evaluated for ADHD, which may contribute to the low prevalence of this disorder. This also
means that teachers usually cannot participate in the ADHD diagnostic process in Vietnam,
whereas in the US it is strongly recommended that the physician talk to the child’s teachers
before making an ADHD diagnosis.
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Figure 11. Map of Vietnam; the cities where one can get evaluated for ADHD by skilled
professionals are marked by red dots (retrieved at https://upload.wikimedia.org/wikipedia/
commons/thumb/3/3f/Vietnam_location_map.svg/1024px-Vietnam_location_map.svg)
Furthermore, mental illness is still considered shameful in Vietnam, especially in more
traditional and rural settings, which discourage people from seeking diagnosis for mental issues
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(Shillabeer, 2016). Due to lack of awareness about mental disorders, many Vietnamese people
still think exclusively of insanity or intellectual disabilities when they hear about mental
conditions. People with insanity and intellectual disabilities are ostracized because they cannot
provide for their families nor fulfill filial duty to their parents, which are frown upon in a society
that values contributions to family and society like in Vietnam. Therefore, people who do not
know about many forms of mental health other than these severe conditions will have a prejudice
against people with mental issues in general. That means even if a family knows of ADHD and
suspects that their child has it, they may try to convince themselves that their child was only
hyperactive rather than accepting the ADHD label, which may mark the child as “abnormal” or a
“burden”. The same kind of stigma exists in the US as well, but it is mostly felt by the children
who saw themselves as “less than normal” when other kids at school see them getting medication
from the nurse office at lunchtime, for example (Bussing et al., 2012). Overall, psychiatry is an
underdeveloped area of medicine in Vietnam. Since ADHD seems very mild compared to other
mental illnesses, Vietnam has not been investing a lot into research and management of ADHD.

Case Studies: ADHD as a developmental disorder
To learn more about first-hand experience of families and children with ADHD in
Vietnam, I interviewed Ms. D, whose son P was diagnoses with ADHD at 18 months of age. An
informal interview was conducted through email with the mother, who also provided her son’s
medical record. P was born in 2014, and when he was 18 months old, Ms. D noticed that he had
difficulty learning how to speak. He also had a high level of activity, often running, jumping and
climbing on furniture. After consulting some sources online, Ms. D took her son to a doctor, who
concluded that P had a developmental disorder after a 30-minute session. Ms. D arranged for her
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son to undergo three therapy sessions at the National Hospital in Ha Noi, each lasting 2-3 weeks.
At the first therapy session, the doctor said P was "hyperactive”. The medical record also
included other diagnostics notes before P started therapy. For example, P apparently rarely made
eye contact, did not respond when called, liked to play alone and rarely imitate the instructor
during play activities. Most notably, the record shows that P was diagnosed with the CARS and
Denver tests, which are meant for diagnosing autism and developmental disorders, not ADHD
specifically. The child was prescribed Risperdal (an antipsychotic used to manage autism),
Trausan (to improve general brain functions) and Magnum Junior (a magnesium supplement to
help with neurodevelopment). However, Ms. D was afraid of the possible side effects of the
medications, so she decided only to use therapeutic activities such as massage, walking bare-foot
on sand, exercising, swimming, drawing, and so on. Ms. D also shared the documents where she
learned about these therapeutic methods, and these are indicated for autism. Finally, P’s medical
record only notes that he has a developmental disorder, without specifying if autism or ADHD
are present (personal communication, 2019).
Another parent interviewed was Ms. X, whose son L was diagnosed with ADHD at 26
months of age. L was also “naughty”, kept running up and down stairs, did not pay attention to
what his parents said, and slow to learn how to speak. The boy was taken to hospitals in Ho Chi
Minh City as well as Ha Noi and got diagnosed with ADHD every time. The doctor prescribed
some medicines, but Ms. X did not remember which brands. In any case, Ms. X decided not to
give medications to L because she read from online sources that medications could not cure the
condition completely and had many side effects. After finding further information from the
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Internet, acquaintances, and other parents with ADHD children, Ms. X chose behavioral therapy
and sought out specialized tutors for L (personal communication, 2019).
These case studies share many common elements and are clearly different from a typical
child with ADHD in the US. First, children are often diagnosed with ADHD in the US once they
started school, since symptoms of inattention and hyperactivity are clearest in an academic
setting (Hinshaw & Scheffler, 2014). Moreover, the earliest age that a child can be evaluated for
ADHD, according to the APA, is 4 years old. In contrast, P was evaluated at 1.5 years old and L
at 2 years old, mostly due to slow speech development and hyperactive behaviors. Since many
young boys are also hyperactive, the chief concern of the mothers in these cases was likely their
sons’ slow speech development, which is not considered a characteristic symptom of ADHD in
the West. Did P and L really have ADHD? It is hard to tell. Even though P’s medical record
shows some signs of inattention, a US physician would probably say that ADHD cannot be
reliably diagnosed at his age. A source of confusion is that while ADHD is translated as “tăng
động giảm chú ý” in Vietnamese, it is often shortened to “tăng động”, which literally means
“excessive movement” or “hyperactivity”. When the doctor says that P is “tăng động”, it could
mean that the child has ADHD, or that he just has hyperactive symptoms. In addition, “tăng
động” is often listed as a symptom or comorbidity of autism in Vietnamese documents, which
explains why P received an ADHD diagnosis while the test used was indicated for autism.
Recently, this confusion between ADHD and autism has garnered more attention, and some
news articles are emphasizing the need to distinguish between these two conditions (T. V. T.
Nguyễn, n.d.; P. Trần, 2018). Therefore, Vietnamese health professionals can hopefully make
more precise diagnoses in the near future.
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As seen from the case studies, Vietnamese parents frequently suspect ADHD in preschool children. This is evidenced by online conversations on ViCare, a popular Vietnamese
website about health issues that allows people to send questions to health professionals. Among
the 30 questions about ADHD on this site, 40% mention that the child is under 4 years old, 33%
mention involves children 4 years of age or older (only 1 child was older than 6 years), and 27%
do not specific the child’s age. While a few doctors answer that children below 4 years old are
too young to tell if they have ADHD, some other health professionals – usually non-psychiatrist
– did not object to the ideas that children under 4 years old can be diagnosed with ADHD. In
addition, a news article notes that for children with autism, ADHD, cognitive deficiency, speech
disorder, etc., 3 years old is the best time for intervention (Thanh Vy, 2017). Therefore, the
motivation for an ADHD diagnosis in Vietnam are often not academic struggles like in the US,
but abnormal development in toddlers, especially slow speech development. In a conversation
with the representative of an herbal supplement for ADHD (Egaruta), I was told that slow speech
development was a symptom of ADHD since inattention made it hard for children to learn how
to speak (Egaruta Health Advisor, personal communication, 2019).
The case studies and my conversation with the Egaruta representative indicate that in
practice, ADHD is not distinguished from other childhood disorders in Vietnam. Instead, it is
often confounded with autism, speech disorder, and so on. While this kind of confusion is rare in
the US, American reserchers also recognize that ADHD has a lot of similarities and a high rate of
overlap with autism and other developmental disoders (CDC, 2018). The reason why Americans
researchers are less likely to confuse ADHD with autism is probably that these disorders were
discovered in different contexts: ADHD is often diagnosed in school-aged children due to
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academic struggles, while autism is often diagnosed in younger children due to communication
issues (Baio et al., 2018; Healthline, n.d.). In Vietnam, however, the ADHD and autism were
both imported into Vietnam as a result of globalization, most likely in the form of a guideline for
health professionals like the WHO’s ICD-10. Before that, nobody had seen, diagnosed or treat
any case of ADHD or autism in the country. Therefore, even though Vietnamese physicians have
the diagnostic criteria, they lack experience in diagnosing and distinguishing between these
highly similar disorders. Just as it took over 50 years for Western scientists to agree on a name,
list of symptoms and diagnostic procedure for ADHD, it will take many years for Vietnamese
physicians to standardize their ADHD diagnosis procedure. At the moment, however, many
children in Vietnam may be misdiagnosed with ADHD while they in fact have some other
condition. Luckily, the negative impact from this potential misdiagnosis is currently small
because Vietnamese people rarely use medications for childhood disorders, as seen in the case
studies, but instead prefer behavioral interventions that are useful for ADHD as well as others
developmental disorders. Therefore, while ADHD is an “academic disorder” in the US and
medicated mostly to improve performance and social relationships, ADHD is a developmental
disorder of early childhood in Vietnam, characteried by parents’ concerns that their children are
not reaching the developmental milestones of their age.

ADHD treatment in Vietnam
Supplies of stimulant medications for ADHD in Vietnam is severely restricted. While
there are at least 27 distinct ADHD medications in the US market, the only ADHD medication in
Vietnam is Concerta, which has only been available since 2016 (Trinh, 2016). In addition, this
medication can be very costly in certain pharmacies. For example, in 2017, a foreigner living in
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Vietnam posted on Reddit that Concerta cost $16 per pill (OhHolyOpals). In comparison, a pill
of Concerta costs about $3.6 in the US (Scheffler et al., 2007). People who responded to the
above Reddit thread also mention that they asked various pharmacies in Ho Chi Minh City, but
none carried Concerta. Although I cannot find documents about the legal status of amphetamine
in Vietnam, people mentioned in similar forums that it is a banned substance. When I inquired
about this at a pharmacy in 2019, it seems the drug is still rare, but the price at some pharmacies
was only about $2 per pill. In any case, supplies of stimulants for ADHD in Vietnam is very
unreliable, and likely absent outside of big cities like Ha Noi and Ho Chi Minh City.
In addition, unlike in the US, Vietnamese publications almost unanimously indicate a
reluctance toward managing ADHD with medications. In a short interview broadcast on the
government’s official television channel, the Head of Psychiatry at the Central Children’s
Hospital (a prominent hospital in Ha Noi) stated that medication was only used for extreme cases
of ADHD as it was not a disease, just a disorder (Thành, 2014). In addition, to get a more
representative sample of the Vietnamese view on this topic, I analyzed 22 websites and news
articles on ADHD from various sources, including the Vietnamese Ministry of Health’s official
website, five popular online newspapers, two health websites dedicated to children’s disorders
and one psychology website. Among them, six texts mention non-drug treatments but no ADHD
medication (27.3%), nine texts downplay the role of medications compared to non-drug
treatments or put them on equal footing (40.9%), four texts highlight the negative side effects
and risks of medications (18.2%), and only two talk about ADHD medications positively and
recommend their use. Among these two, one is specifically about managing adult ADHD, and
the other one is based on WebMD. Among the texts that downplay the role of ADHD
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medications, most of them state that medications are only required for severe cases and must be
used with care due to possible side effects. Most notably, one of the articles examined was
sponsored by the pharmaceutical company Janssen Cilag – the manufacturer of the only ADHD
medication in Vietnam. Surprisingly, the article does not mention any medication or other
treatments for ADHD at all, and instead offers only a detailed list of symptoms. It seems that
Vietnam has effectively enforced the UN’s convention against marketing psychotropic drugs to
consumers. Overall, if the site is based on an English source, it is more likely to mention ADHD
medications. Details about the articles and websites analyzed are in the Appendix.
Rather than stimulants, behavioral therapy and acupuncture seem to be the most popular
treatments for ADHD. In the aforementioned interview, the Head of Psychiatry at the Central
Children’s Hospital also stated that their interventions mostly consist of counseling parents of
children with ADHD on how to improve the children’s attention and control their behaviors. In
addition, a guideline published in 2015 by the Vietnamese Ministry of Health listed cognitive
behavioral therapy, life skill coaching, play therapy, group therapy and family counseling as
interventions for ADHD, which are similar to treatment choices in the US (Nguyễn, Lê, &
Lương, 2015). The same guideline also notes that psychological therapy, including cognitive
behavioral therapy, play therapy, drawing, and relaxation, can be used for many childhood
disorders including ADHD, providing further evidence that ADHD is not separated from other
childhood disorders in Vietnam.
While behavioral therapy is a well-known treatment for ADHD over the world, Vietnam
also has a more obscure treatment for this condition, which is acupuncture (Hương Anh, 2014).
Before being applied to ADHD, acupuncture has been a popular treatment for autism in children
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in Vietnam. ADHD shares many symptoms with autisms, so some health professionals have tried
treating ADHD with acupuncture as well (Bạch Dương, 2017). Nevertheless, studies carried out
in other countries have found no significant proof that acupuncture is beneficial for children with
autism or ADHD (Cheuk, Wong, & Chen, 2011; Lee, Choi, Kim, Kim, & Ernst, 2011). Only
anecdotal evidence is available, as some Vietnamese magazine articles report that acupuncture
helps with continence, sleep disorder, attention problem, and other symptoms in autistic children
(Thanh Vy, 2017; Thúy Quỳnh, 2018). Like neurofeedback in the West, acupuncture has the
potential to be a new treatment for ADHD, but more clinical trials are needed to assess its
effectiveness.

5. Cultural and economic drives behind Vietnam’s aversion to
ADHD medications
The Vietnamese’s preference for non-drug treatments in managing ADHD was shaped by
many factors. One of them is the coexistence of traditional medicine and Western medicine in
Vietnam. Since the end of the French colonialism, traditional medicine has been promoted by the
new Vietnamese state as a means of self-sufficiency in times of shortage and a source of
nationalist pride. Therefore, Vietnamese traditional remedies are seen as indigenous and benign
whereas Western medications are seen as efficacious but aggressive in the public imagination,
leading to heightened wariness about the side effects of Western ADHD medications. This
situation also allows Vietnamese herbal supplements to compete effectively with Western
ADHD medications, and the manufacturers of those supplements have their own tactics to
promote their products. Therefore, just as reductionistic biomedicine and the pharmaceutical
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industry promote ADHD medication use in the US, traditional medicine and local herbal
supplement industry encourage non-drug treatments in Vietnam. Lastly, while students in both
countries experience enormous academic pressure, educational policies in the US make ADHD
diagnosis a solution to relieve this stress while policies in Vietnam do not.

Influence from Vietnamese traditional medicine
Besides China and Korea, Vietnam is one of the few countries whose traditional medicine
is highly integrated into the modern network of health services (Wahlberg, 2006). Vietnamese
traditional medicine, often called “Đông Y” or Eastern medicine to differentiate it from Western
medicine, was heavily influenced by Chinese traditional medicine, but also adapted to the unique
pathology and medicinal plants of Vietnam (Wahlberg, 2006). In the 2002 book Familiar
Medicine: Everyday Health Knowledge and Practice in Today's Vietnam, David Craig offers a
brief but informative history of different medical traditions in Vietnam, including Eastern and
Western medicines. Like in feudal China, the majority of educated men in feudal Vietnam took
exams to become government officials, and when they failed, often turned to the field of
traditional medicine instead. Traditional healers often kept formulas for herbal remedies in their
families, except for a few famous healers who wrote comprehensive books about diagnosis,
medicinal herbs and remedies. Traditional Vietnamese medicine was completely unregulated
before the 20th century, except when a patient died and the healer might face a charge (Craig,
2002). Therefore, the skills of traditional healers and the people’s confidence in them varied. In
any case, before the 20th century, traditional medicine was the only source of remedies that
Vietnamese people had access to. “When you are sick, try all possible remedies”, so says a
Vietnamese proverb, since even the most established treatment may fail. Consequently, aside
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from traditional medicine, sick people often turned to religious and superstitious ceremonies to
pray for recuperation, which is still common in some areas.
Western medicine, first brought to Vietnam by the French colonizers, was a means of
governing rather than caring for the local populace. First, it represented the export of French
culture and civilization, a way to legitimize French rule over the “unenlightened” Vietnamese
people since the French were supposedly helping to develop the country. Second, Western
medical facilities were built to support French troops and maintain the economic productivity of
plantations and mines. Civilian medical service was available to urban elites between 1905 and
1945, when Vietnamese independence was first established from the French, but benefited only
about 3% of population in 1937, most of them colonizers. The French also opened the Hanoi
Medical School in 1905, the first modern university in Vietnam. However, overall only 4% of
colonial budget was spent on health services, 60% of which used for salaries of French officials.
Public health in rural areas changed little, except for declining food security and nutritional
status due to exploitation, culminating in famine and epidemics during WWII. Overall, the
French did little to change health system, leaving most of the traditional medical practices
untouched, and even took back the resources from medical facilities in Northern Vietnam before
their final departure in 1954 (Craig, 2002). Therefore, despite the century-long French
occupation, reductionistic ideas associated with Western medicine had not really taken root in
Vietnam by 1954, which most likely played a role in the prominence of Vietnamese traditional
medicine today and the Vietnamese’ lukewarm attitude toward Western medications.
The new Vietnamese government, the Democratic Republic of Vietnam (DRV),
capitalized on the failure of the French to build a public health system and created a nationalist
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movement based on traditional medicine. The DRV emphasized community health work as proof
of their commitment to the wellbeing of the people, a central socialist tenet, and contrasted this
with the French colonizers’ selfish agenda. Since Western medicines were scarce since the
Vietnamese revolution against the French until the lifting of American embargoes on Vietnam in
the 1980s, the new “people’s medicine” heavily relied on traditional healers and remedies. At the
time, there were about 18,000 traditional healers compared to about 200 Western doctors and
assistant physicians (Craig, 2002). That was how traditional Vietnamese medicine became a
nationalist banner and an anticolonialist weapon.
Traditional medicine became stagnant for a few years when Western medicines became
available in Vietnam following the economic reform of 1986, but was revived in 1992 by the
state to create a “scientific, national and popular” traditional medicine that can stand as
counterpart to Western medicine (Wahlberg, 2006). Important initiatives included taxonomizing
many medicinal herbs and industrializing them. Traditional medicine was further standardized
through the government’s efforts to integrate it into medical colleges’ curriculum, create
professional associations for traditional health practitioners and license their practice. The
Vietnamese Association of Traditional Practitioners was estimated to have about 20,000
members in 2003 (Wahlberg, 2006). In other words, traditional Vietnamese medicine is being
subjected to similar regulations and quality control measures as Western biomedicine in Vietnam
in terms of safety, efficacy, and professionalism.
As a result, although traditional medicine still has less funding and prestige than Western
medicine in Vietnam nowadays, traditional medicine is developed enough to offer a viable
alternative to Western medicine. Vietnamese people thus have choices and have to choose
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between these antithetical systems when seeking treatment for various illnesses, including
ADHD. Like most traditions of alternative medicines around the world, traditional Vietnamese
medicine aims to enhance the body’s resilience and re-establish its balance (Wahlberg, 2006).
Consequently, tonics like ginseng play the central role in traditional Vietnamese medicine. They
are not indicated for a specific disease but meant to enhance strength of the whole body, and
account for more than half of all Vietnamese traditional ingredients. In contrast, Western
biomedicine is reductionistic, so it focuses on attacking a single pathogen or molecular cause of
disease rather than considering the whole organism (Craig, 2002; Wahlberg, 2006). Overall,
Vietnamese people prefer Western medicine for diseases with established Western treatments,
including infections and most acute conditions. Meanwhile, diseases commonly dealt with by
traditional medicines are those without effective Western treatments like certain chronic diseases
and minor injuries like a sprained ankle. ADHD belongs to the second category. Some people,
especially the urban elites, look down on traditional medicine as obsolete and inferior to Western
rational medicine; however, they only make up a small portion of the population as 64.3% of the
population live in rural areas (Craig, 2002; Vietnam Bureau of Statistics, 2018). It is much more
common for the patient to combine traditional remedies and Western medications, oftentimes
without informing the doctor since traditional products often take the form of herbal supplements
and thus viewed as safe to take concurrently with other drugs.
In this process of deciding between traditional and Western treatments, the Vietnamese
public has formed several ideas about both medical systems, which play a key role in the
Vietnamese preference for traditional remedies over Western medication for ADHD. For
example, traditional medications are considered familiar, benign, natural, slow-acting cooling,
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and restorative for the body’s humoral balance. In contrasts, Western medications are seen as
alien, powerful, aggressive, synthetic, fast, hot, and will harm the body’s integrity in order to
eliminate a specific cause of disease. This view seems largely informed by the Vietnamese’
perspective on antibiotics (the first Western medicine that were widely available in Vietnam),
which kill good as well as bad bacteria and cause heat-related problems like mouth ulcers (Craig,
2002). Children are seen as weaker than adult, so their use of Western medications must be
restricted so that their long-term health is not damaged by the powerful medications. Similarly, if
the condition is mild, people often think that traditional medications would suffice and
aggressive Western medications are unnecessary. This applies to not only psychotropic
medications but also medications for diarrhea, for example (Craig, 2002).
ADHD has both of the aforementioned characteristics: the patients are usually children,
and it seems much milder than other diseases like diarrhea or dengue fever. Behavioral therapy,
albeit Western in origin, does not count as it introduces no new substance into the body. That is
why Vietnamese texts and the two interviewed mothers – Ms. D and Ms. X – were so concerned
about the side effects of ADHD medications and prefer behavioral or traditional treatments.
Furthermore, this explains why several Vietnamese texts advise that Western ADHD
medications be used only for adult or to manage severe symptoms. This reasoning may seem odd
and irrational from a Western perspective, but parallel trends exit in the US as well. For instance,
adult usage of ADHD medication, especially the more powerful amphetamine, is overtaking
youth usage of ADHD medication in the US (Safer, 2016). In addition, a 2012 study found that
American teachers thought behavioral therapy was more suitable for girls, possibly because their
symptoms usually appear milder than boys’ (Bussing et al.). Therefore, despite large differences
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between the American and Vietnamese medical systems, they still share some common ideas
about ADHD medication.

The herbal supplement industry in Vietnam
Parallel to the US, corporate interest plays a role in shaping the Vietnamese’s treatment
choice for ADHD. The difference is that while US corporations make money from synthetic
medicines, Vietnamese companies rely mostly on traditional herbal products. One reason for this
is that Vietnam does not have enough resources to invest in rational drug design like the US.
Compared to new synthetic drugs, herbal supplements are easier and cheaper to make since the
ingredients are abundant locally and the medical effect of many herbs are known. Development
of traditional remedies into industrial products is also encouraged by the government as a way to
take advantage of the country’s rich traditional medicine and wide range of medicinal herbs
(Vietnam Ministry of Health, 2015). In 2014, 2000 out of 10,000 medicines on VN market are
classified as herbal medicines. The government also passed laws requiring herbal ingredients and
products to meet quality, safety, efficacy standards, as tested by the Vietnamese Institute of Drug
Quality Control (Wahlberg, 2006). Governmental policies supporting herbal supplements extend
to universities as well, since students in programs like Pharmacy must learn the identification
and benefits of 90 Vietnamese medicinal herbs (Đỗ, T. M. N., personal communication, 2016). A
lot of medical research in Vietnam centers on developing new herbal cures to diseases as well
(Đỗ, H. Đ., personal communication, 2015). Overall, the herbal supplement industry in Vietnam
is highly regulated and promises to keep expanding in the future.
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Like pharmaceutical corporations in the West, Vietnamese producers of herbal
supplements for ADHD employ a range of strategies, from normal to misleading ones, to
promote their product. While psychotropic medication cannot be advertised directly to
Vietnamese consumers, herbal supplements apparently can. Therefore, many companies create
websites with articles written by health professionals on ADHD, autism, and related
developmental disorders while highlighting the benefits of their supplements and the negative
side effects of pharmaceuticals. Examples include https://benhtangdong.com.vn and
http://roiloanphattrien.vn (site names say “hyperactive disease” and “developmental disorder”,
respectively), which promotes two different supplements for ADHD by the same company:
Egaruta and Vương Não Khang. Each website has a chat window that allows visitors to ask
questions to company representatives, including some health professionals, about the conditions
and products. Consequently, exposure to these websites and interactions with the representatives
likely makes Vietnamese parents prefer ADHD supplements to medications. Another strategy
that the company uses to increase sale is claiming that ADHD diagnosis and treatment is most
effective when the child is 3 years old (Egaruta Health Asvisor, personal communication, 2019).
Given that the two websites draw a lot of information from American sources like WebMD, they
must have deliberately lowered the youngest age for ADHD diagnosis from 4 to 3 years old to
increase ADHD prevalence and product sale. Although Vietnamese corporations have much
less influence on researchers, advocate organizations, and consumers than Western corporations,
the Vietnamese government should still beware of the way they are misrepresent facts to gain
more profits.
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Academic pressure and ADHD in Vietnam
The social factors we have seen so far have different effects on ADHD diagnosis and
treatment in Vietnam. The lack of awareness about ADHD and facilities for ADHD diagnosis are
keeping ADHD prevalent low in Vietnam, but they are not likely to have a big impact on
treatment choice. The status of Vietnamese traditional medicine and the marketing efforts of
herbal supplement manufacturers both restrict the use of Western medication to treat ADHD, but
Vietnamese traditional medicine does not affect ADHD diagnosis rate, while herbal supplement
manufacturers actively encourage ADHD diagnosis. Another social factor that likely promotes
ADHD diagnosis is academic pressure, which is also a key factor in the emergence of ADHD in
the US. East Asian countries like China and Korea are notorious for putting tremendous pressure
on children to succeed academically, and Vietnam is quite similar. For many Vietnamese people,
good academic result is a source of pride and honor for the family and the only way out of
poverty. While Vietnamese parents are not watching out for ADHD in school-age children at the
moment, as awareness about ADHD increases, will they start to demand more ADHD diagnosis
and treatment to give their children an advantage at school?
There is a good chance that once the link between ADHD and academic struggle is more
well-known in Vietnam, ADHD diagnosis rate will increase. However, ADHD prevalence and
treatment will not reach the same magnitude in Vietnam as in the US, at least in the near future,
for three reasons. First, while American students can obtain educational accommodations if they
have ADHD, students in Vietnamese public schools have no such service. To receive an
education tailored to their individual needs, students with ADHD must enroll in special
education schools, which are more expensive and have much lower capacities than traditional
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public and private schools. In addition, just like facilities for ADHD diagnosis, special education
school for ADHD may not be available in small cities and rural areas. Second, stimulant
medications are very rare in Vietnam. If students cannot receive educational accommodations or
medications, then being diagnosed with ADHD has no immediate benefit. While students with
ADHD can still be treated with behavioral therapy, this requires coming to a big city like Ha
Noi, Da Nang or Ho Chi Minh City for weeks at a time. Even if this can be arranged during the
summer vacation, it is still inconvenient for people living outside these three cities because most
Vietnamese students aged 10 and above take supplemental classes in the summer as well.
Consequently, arranging behavioral therapy for a pre-school child is much easier than an
adolescent. The most accessible type of help for adolescents with ADHD is private tutor, which
can be obtained without an ADHD diagnosis. Finally, unskilled and manufacturing jobs are
abundant in Vietnam, so students who do not succeed academically can still make a living.
Vietnam takes vocational education seriously and requires most students in public schools to
take a vocational class during high school. Therefore, although students and parents in Vietnam
face tremendous academic pressure, its effect on ADHD diagnosis and treatment will be small
because the country lacks the infrastructure to offer academic help to students with ADHD.

6. Conclusion
As noted by Bergey and Conrad (2018), the US could be considered the “epicenter” of
ADHD. This country has witnessed the first clinical trials showing the effects of stimulants on
inattentive and uncontrollable children, the birth of the name “ADHD”, and fierce debates on
whether ADHD is being overdiagnosed and overmedicated. The problem is, due to lack of data
on the true prevalence and lack of a consensus on the appropriate level of stimulant use for
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ADHD, we have no basis to judge whether ADHD is being overdiagnosed and overmedicated.
Therefore, the government should compile a comprehensive data set on ADHD prevalence and
diagnostic practices across the country to check whether ADHD diagnosis is being inflated. The
US is also facing many local problems that must be quickly addressed, including the wide
variation in ADHD prevalence in different states and demographic groups, simulant diversion,
and stimulant misuse to enhance performance. There are two possible solutions for this problem.
One solution is diagnosing only moderate and severe cases of ADHD, like in some European
countries, so that people with only mild ADHD symptoms are not exposed to the risks of
stimulants. However, many Americans will find this solution unsatisfactory, since children and
adults with mild ADHD symptoms still face disadvantages at school and at work. The alternative
is classifying ADHD cases into mild, moderate and severe cases, with restricted medication use
for mild cases. This method requires more time and efforts, but it can ensure that people with
mild ADHD still benefit from educational accommodations and other services.
The US has built an impressive infrastructure to support people with ADHD, including
accessible diagnosis and treatments for the majority of the population, health insurance coverage,
and special educational programs. Advertisement campaigns and advocacy organizations have
also increased awareness, reduced the stigma and promoted scientific research into this
condition. However, underneath these advances are social structures that encourage people to
take on the label of ADHD for their children or themselves, so that they are eligible for
medications, educational accommodations, and other services. These structures include Big
Pharma’s profit-driven marketing campaigns, American psychiatry’s habit of relying on
mediations, and the increasing demand for academic success in the US. These factors do not
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invalidate ADHD as a legitimate behavioral disorder: many people with this condition do need
medications and other treatments. However, when the major forces driving ADHD diagnosis and
treatment forward are corporate interest and academic competition rather than simply curing a
medical disorder, we face the danger of emotionally burdening children with the ADHD label,
giving psychotropic drugs to people who do not need them, and saturating the market with
substances with high potential for abuse. In other words, the rise of ADHD will not cease when
we have identified and treated everyone with ADHD, but rather when Big Pharma no longer
wants more profit and society stop raising the bar on academic success. Given the alarming
increase in amphetamine and methylphenidate production in the US in the past few decades, it is
high time we take back control of the ADHD engine and make sure children and adults with the
condition take the highest priority in ADHD diagnosis and treatment.
The situation in Vietnam is the opposite. The concept of ADHD was imported into the
country not too long ago, so the demand for diagnosing and treating these conditions is still low
in general, but slowly rising as a result of globalization. At the moment, though, not much
research has been done on ADHD in Vietnam. Medical facilities for diagnostic and treatment of
ADHD are also severely lacking, so people living in small cities and rural areas must travel to
big cities just for a diagnosis, if they have heard about ADHD at all. In addition, Vietnamese
health professionals likely learned about ADHD at the same time as numerous other childhood
disorders such as autism, oppositional disorders, speech disorders, without any prior experience
in distinguishing these conditions. ADHD is thus often confused with conditions like autism and
speech disorders in Vietnam. Therefore, a priority for Vietnam in the future would be
systematizing the diagnosis and treatment of ADHD so that people affected by this condition
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may receive the precise treatments that they need. In addition, as more and more students are
diagnosed with ADHD and other learning differences, the Vietnamese government and schools
should start providing education accommodations or other forms of academic assistance for
those students.
Since ADHD diagnosis and treatment in Vietnam lacks a refined structure, the
opportunity exits to create a more balanced system that is not as strongly influenced by
pharmaceutical companies and academic pressure as in the US. Currently, traditional Vietnamese
medicine provides products and ideas that serve as counterpoints to Western medications and
perspectives. Influenced by traditional Vietnamese medicine, people in Vietnam often view
Western medications as highly effective, but also harmful for the body if used for a long time.
This leads to an unwillingness to medicate children with ADHD, especially since the symptoms
are not very severe compared to infectious diseases and other conditions. While this perspective
is very conservative and seems unscientific to a Western audience, it may be warranted given the
high potential for abuse of stimulants and the widespread stimulant misuse in the US. In the end,
each country has to make its own decision on how to balance the risks and benefits of stimulant
medications for ADHD. Future research on ADHD in Vietnam should aim to test the
effectiveness of traditional remedies like herbal supplements and acupuncture in treating ADHD.
In addition, it will be interesting to see if ADHD will evolve into an “academic disorder” like in
the US over time, although there is little motivation for this change at the moment.
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